The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

12-2014

ROLE OF PHOSPHORYLATION OF FOCAL ADHESION KINASE AT
TYROSINE 861 IN PROSTATE CANCER METASTASIS
Tanushree Chatterji

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Biology Commons, and the Cancer Biology Commons

Recommended Citation
Chatterji, Tanushree, "ROLE OF PHOSPHORYLATION OF FOCAL ADHESION KINASE AT TYROSINE 861 IN
PROSTATE CANCER METASTASIS" (2014). The University of Texas MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 530.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/530

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

ROLE OF PHOSPHORYLATION OF FOCAL ADHESION
KINASE AT TYROSINE 861 IN PROSTATE CANCER
METASTASIS
by
Tanushree Chatterji, M.S.

APPROVED:

_____________________________________
Gary E. Gallick, Ph.D., Supervisory Professor

____________________________________
Menashe Bar-Eli, Ph.D.

____________________________________
David J. McConkey, Ph.D.

___________________________________
Jian Kuang, Ph.D.

_____________________________________
Scott E. Kopetz, M.D., Ph.D.

APPROVED:

_____________________________________
Dean, The University of Texas
Graduate School of Biomedical Sciences at Houston

ROLE OF PHOSPHORYLATION OF FOCAL ADHESION
KINASE AT TYROSINE 861 IN PROSTATE CANCER
METASTASIS

A
DISSERTATION
Presented to the Faculty of
The University of Texas
Health Science Center at Houston
and
The University of Texas
MD Anderson Cancer Center
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of

DOCTOR OF PHILOSOPHY
by
Tanushree Chatterji, M.S.
Houston, Texas
December 2014

DEDICATION
This dissertation is dedicated to my parents Priyabrata and Krishna, supportive husband
Venky, my loving sister Anushree and brother-in law Dhanesh.

iii

ACKNOWLEDGEMENTS
I would like to convey my deepest gratitude to my mentor, Dr. Gary Gallick for his tireless
efforts and immense support, patience and encouragement during the duration of this degree.
I wish to thank my committee members Drs. Scott Kopetz, Menashe Bar-Eli, Jian Kuang, and
David McConkey for their contribution, supervision, and ideas during this dissertation work.
I wish to thanks members of Dr. Gallick’s laboratory, Nila Parikh, Andreas Varkaris, Jian
Song, Lynnelle Thorpe, Sanchaika Gaur and Jung Kang Jin for their help, friendships, advice
and encouragement during this degree.
I wish to thank the Genitourinary Medical Oncology Research program for providing me with
the resources required to complete the dissertation work and the Graduate School of
Biomedical Sciences for their financial support.

iv

ROLE OF PHOSPHORYLATION OF FOCAL ADHESION
KINASE AT TYROSINE 861 IN PROSTATE CANCER
METASTASIS
Tanushree Chatterji, M.S.
Supervisory Professor: Gary E. Gallick, Ph.D.
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that mediates
interactions between the extracellular matrix and intracellular signaling pathways critical in
promoting numerous cellular functions including adhesion, proliferation, survival and
migration. Most FAK functions result from phosphorylation by Src family kinases, which
trigger numerous signaling cascades. Overexpression of FAK is associated with metastasis in
many solid tumors, including prostate cancer. Hence, understanding the mechanisms by which
FAK is regulated in prostate cancer will better elucidate its role in prostate cancer metastasis.
Work in this dissertation tested the hypothesis that altered phosphorylation of FAK is critical
for cell migration and promotion of prostate cancer metastasis.
To address the hypothesis, I developed highly migratory variants of prostate cancer
cells. These cells were increased in invasion, decreased in adhesion and had increased
metastatic potential. A hallmark of the migratory variants was increased phosphorylation of
FAK Y861. To examine the mechanism for this increased phosphorylation, expression and
activity of Src family members were assessed. The migratory variants were increased in
expression and total activity of the SFK, Yes, but no other members of the Src family kinases.
I demonstrated that Yes was specifically responsible for the phosphorylation of FAK Y861
using both prostate tumor cells and src-/-, yes-/-, fyn-/- mouse embryo fibroblasts and that
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increased Yes expression was directly responsible for increased migration of the selected
migratory variants. Using shRNA plasmids directing knockdown of Yes, I further
demonstrated that silencing Yes inhibits prostate cancer lymph node metastasis in vivo in an
orthotopic model of prostate cancer tumor growth and metastasis. Furthermore, in human
specimens, I demonstrated that Yes expression and phosphorylation of FAK Y861 was
increased in lymph node metastases relative to primary tumors, with the latter correlating with
decreased patient survival.
In summary, I have identified novel roles for Yes in selectively phosphorylating FAK
relative to other SFKs, resulting in increased migration and metastasis of prostate cancer cells.
Therefore, increased expression of phosphorylated FAK at tyrosine 861 and Yes kinase may
be predictive markers for prostate cancer progression.
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Introduction
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Prostate Cancer (PCa) is the most commonly diagnosed form of cancer and the second
leading cause of death due to cancer in men in the United States [1]. According to The American
Cancer Society, there will be 233,000 estimated new cases of prostate cancer and 29,400 men
are expected to die due to the disease in 2014. Localized disease is almost always curable, with
a survival five-year rate exceeding 99% [2]. Hence, for patients with early stage localized
disease, “active surveillance” is often recommended [3]. Nevertheless, many patients, even
those diagnosed at a relatively early stage will choose radical prostatectomy, proton therapy or
external radiation beam therapy because prediction of prognosis of prostate cancer is still
unclear [4-6]. Additionally, many patients with early stage prostate cancer may choose to opt
for androgen-ablation strategies as inhibition of the levels of androgens by androgen-ablation
therapy leads to anti-tumor effects in early stage prostate cancer [6].
Prostate cancer, in its early stages, has few overt symptoms, hence, without performing
a biopsy, diagnosis of prostate cancer in patients is challenging. Currently the biomarker used
by some clinicians to guide diagnosis of prostate cancer is elevated levels of prostate-specific
antigen (PSA) [7]. Presence of high serum levels of PSA (<4.0ng/mL) indicates, in some men,
increased probability of having prostate cancer [8]. However, PSA is secreted by both normal
and tumor prostate epithelial cells and increase in PSA concentration often occurs due to other
factors such as increasing age and inflammation of the prostate [9]. On the contrary, low levels
of PSA do not always indicate absence of prostate cancer [7]. The difficulty with PSA as a
predictor of prostate cancer is illustrated by of two recent clinical trials by Andriole et al., 2009
and Schröer et al. 2009. These trials have resulted in a controversial recommendation by the
United States Preventive Services Task Force (USPSTF) against prostate cancer screening
using PSA. However, regardless of the recommendation, The American Cancer Society
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recommends that men at age 50 should discuss the benefits and limitations of PSA testing with
their health care providers. High concentrations of PSA often lead to biopsies, which are more
diagnostic.
If patient is biopsied, staging of the cancer is performed by the five-tier Gleason grading
system [10]. The grading consists of the sum of two scores from well-differentiated pattern to
most poorly differentiated pattern ranging 1-5, necessary because of the heterogeneity of the
tumor. The most prevalent pattern (observed in more than 50% of the tumor) is the primary
score and the second most prevalent pattern (observed in less than 50% but more than 5% of
the tumor) is the secondary score ranging from 1-5. A low Gleason score of 2-6 has a five-year
recurrence-free survival risk of 94.6%. As the Gleason score increases to 7 (3+4 or 4+3),
recurrence-free survival risk drops to 82.7% and 65.5% respectively. Gleason score of >7 is
considered high-grade cancer with the highest scores 9-10. Patients with Gleason scores of 9 or
10 have the five-year recurrence free survival of 34.5% [11]. While treatment for patients with
Gleason scores >7 is always recommended, which lower grade tumors will progress and which
may never progress during a man’s lifetime is not clear. Thus developing better biomarkers to
predict prostate cancer progression is of high priority. Considerable focus has been made on
whole genome sequencing, SNP analysis, etc., to develop novel biomarkers, but these
approaches have not led to an easily assayed serum marker.
Deaths from prostate cancer primarily arise from metastasis that can occur to several
organs such as lungs, liver, brain and in 80% of prostate cancer cases, to the bone [12]. The
five-year survival rate of metastatic prostate cancer drops drastically to 31% from 99% [2], as
current therapeutic regimens have little effect on improving long-term survival of patients
afflicted with metastasis [13]. Therefore, gaining a better understanding of the mechanisms by
-3-

which prostate cancer metastasizes is critical to developing novel therapies for this late-stage
disease.
Some progress has been made in treatment of metastatic disease. In the last three years,
several drugs that have been approved by the Food and Drug Administration (FDA) for
treatment of metastatic prostate cancer, including Abiraterone Acetate [14], Enzalutamide [15]
and Bicalutamide [16]. These drugs have been based on numerous studies that indicate that
even late castrate-resistant metastatic disease are still “driven” by the androgen/AR pathways
[17], and these drugs inhibit AR-driven genes by different mechanisms. More recently,
advances in immunotherapy have led to considerable promise for the treatment of several
tumors, including prostate cancer [18]. These include FDA approval of Siuleucel-T and
Ipilimumab [2, 19-21]. These drugs have improved patient survival; however, few if any
patients are cured by these new agents [22]. A major cause of short survival is development of
resistance, in which compensatory signaling pathways still drive metastatic growth [23-25].
Hence, understanding both the mechanisms of resistance and mechanisms that lead to
metastasis may provide new biomarkers and therapeutic targets. These advances in therapy may
come from understanding the genetics and epigenetics of prostate cancer (discussed in the next
sections), along with understanding the alterations in the androgen/AR pathway that drive
prostate cancer progression (discussed later).
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Genetic alterations in prostate cancer
Genetic changes in prostate cancer are fewer than in many other solid tumors, although
many have been identified as summarized in a recent review by Boyd et al.[26]. Through several
strategies, gains and losses of chromosomes have been observed. Gain of chromosome 8q is
observed in 34% of prostate cancer cases and losses at chromosomes 3p, 8p, 10q, 13q, and 17p
are observed in 30-50 % of prostate cancer cases [27-29]. Some of the key regulatory genes that
are located within this region, including NKX3.1 at 8p21, PTEN at 10q23, MYC at 8q24, and
fusion of TMPRSS2 and ERG both located at 21q22.3 to form TMPRSS2:ERG [30]. Some of
their roles in prostate cancer initiation and progression will be discussed below briefly.
Loss of NKX3.1
NKX3.1 is a tumor suppressor gene and a transcription factor that is a critical regulator
of prostate epithelial differentiation. It is located on chromosome 8p21.2 NKX3.1 shows loss of
heterozygosity (LOH) in 20% of high-grade intra epithelial neoplasia (PIN), a precursor to
prostate adenocarcinoma and 78% of metastases [31]. Evidence that it is important in prostate
cancer progression has been developed from genetically engineered mouse models that indicate
that deletion of a single NKX3.1 allele or complete knockout results in hyperplasia or dysplasia
in prostate cancer mouse models [32, 33]. Studies have indicated that prostate glands of NKX3.1
null mutant transgenic mice resemble histopathological alterations of human PIN [34-36] and
NXX3.1 null mice have the characteristics of early stages of prostate cancer [37]. Hence, these
findings strongly suggest NKX3.1 is a tumor suppressor gene that prevents prostate cancer
initiation.
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Loss of PTEN
Phosphatase and tensin homolog (PTEN) is a lipid-phosphatase that de-phosphorylates
the 3 position of the inositol ring of PtdIns (3,4,5)P3 and thus inactivates several pathways, one
of the major ones is the protein kinase B/AKT kinase pathway, critical in survival and growth
of prostate cancer [38]. It was identified as a tumor suppressor gene and is located on
chromosome10 q23 normal epithelial cells [38-41]. PTEN undergoes allelic loss in observed in
20-30% prostate cancers[42] and epigenetic silencing of PTEN is observed in 60% prostate
cancers[40]. Studies with genetically engineered mice with knock out of PTEN have indicated
that deletion of PTEN in mice causes PIN, followed by progression to invasive adenocarcinoma
[43]. Additionally, loss of PTEN also promotes progression to castration-resistant prostate
cancer [44]. These data indicate that PTEN loss promotes prostate cancer progression.
TMPRSS2:ERG
TMPRSS2:ERG is a fusion gene consisting of the TMPRSS2 located on 21q22.3,
regulated by androgens, which can be fused to the transcription factor ERG located on
chromosome 21q22.2 from the ETS family [45]. This fusion gene is found in 50% of prostate
cancers, implicating that presence of TMPRSS2:ERG fusion can be a critical event in prostate
cancer progression leading to androgen-regulated high expression of a transcriptionally active,
N-terminal truncated ERG protein that contributes to prostate cancer development and
progression [46]. Transgenic expression of this fusion gene in mouse models results in PIN
lesions, loss of PTEN and activation of the PI3K pathway leading to prostate cancer initiation
[47]. Together, these data indicate that TMPRSS2:ERG fusion is critical in prostate cancer
initiation and progression.

-6-

MYC upregulation
MYC is a transcription factor that regulates variety of cellular processes [48]. It is located
on chromosome 18q24 which is amplified ~40% of the primary tumors and ~90% in prostate
cancer metastases [49]. Studies using genetically engineered mouse models indicate that
overexpression of MYC in the prostate of transgenic mice induces formation of PIN, leading to
invasive prostate adenocarcinoma[50]. Transgenic mice overexpressing MYC when crossbred
with PTEN-null mice developed high-grade PIN, which progressed to prostate cancer [51].
Collectively these data indicate that upregulation of MYC is associated with prostate cancer
initiation and progression. In summary, while these genetic alterations may lead to biomarkers
important in prostate cancer initiation or progression, none to date has resulted in targeted
therapies.
Androgen signaling in prostate cancer progression
Although genetic alterations are required for prostate cell transformation and cancer
initiation, AR signaling is the driver of prostate cancer at early stages. Binding of androgen to
AR leads to formation of an androgen/AR receptor complex that translocates to the nucleus and
binds to AR-responsive elements, and orchestrates transcription of androgen-regulated genes
[52]. Activation of androgen-regulated genes promotes cell survival, proliferation and
prevention of apoptosis of cancer cells [53]. Hence, inhibition of the levels of androgens by
androgen-ablation therapy leads to anti-tumor effects in early stage prostate cancer also known
as the “endocrine-phase” of prostate cancer [54].
As prostate cancer progresses under androgen-ablation selection pressure, the tumor
evolves and escapes dependence on androgen entering the “paracrine-phase” [54]. In this phase,
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the disease is not only driven by androgens but also numerous stimuli/molecules secreted from
the microenvironment [54]. Hence, the “paracrine-phase” of tumor development involves both
the tumor and the microenvironment to promote metastasis. Collectively, the “endocrine-phase”
and the “paracrine-phase” lead to development of prostate cancer metastasis, which does not
respond to chemotherapeutics leading to mortality of patients. Therefore, in the next section, I
will briefly describe the metastatic process in prostate cancer and the selected signaling
pathways that are associated with metastasis relevant to my thesis work that may lead to novel
therapeutic approaches.
Prostate cancer metastasis
As the vast majority of deaths due to prostate cancer result from metastases, mostly to
the bone but also to the viscera and a better understanding of the metastatic process is required
to develop novel therapies that will prolong survival. The metastatic process is extremely
inefficient but selective, with less than 0.1% of the cells that enter the circulation, surviving to
form metastasis at the distant sites [55]. The classical model of metastasis, the “seed and soil”
hypothesis was first proposed by Stephen Paget in 1889, which states that tumor cells (seeds)
only metastasize to specific organs (soil) that facilitate their growth [56]. Work that is much
more recent has led to the understanding that the tumor microenvironment at the metastatic site
plays an important role in the development of the “soil” that facilitates the process of metastasis.
Classically, as defined by Fidler et al.[57], the metastatic process has been described as
a series of individual but linked steps including angiogenesis, migration, invasion, intravasation,
circulation, extravasation and finally, colonization in distant organs [58]. Several models have
been described to understand the progression of these steps. One model is the “linear
progression model” that states that cancer cells pass through multiple successive rounds of
-8-

mutations to select for cells with competitive fitness in the context of the primary tumor to go
through above mentioned steps in metastasis [59]. The tumor cells that can survive and
proliferate at a competitive rate, expand and subsequently leave the primary tumor sites to
colonize on the secondary sites [59]. However, dissemination of tumor cells can occur early
(when the primary tumor is small). The second model is the “parallel progression model”, that
states that metastasis can occur in parallel to the development of the primary tumor and this
model does not consider the occurrence of dissemination of cells as a later phenomenon after
development of primary tumor [60]. Moreover, dissemination of cells can occur during the
development of primary tumor as the cells adapt to the tumor microenvironment [59].
In spite of the presence of the different models that define cancer progression, a critical
process that facilitates metastasis in both these above-described models is bidirectional
interactions between tumor cells and microenvironment, occurring both at the primary and
metastatic sites. At the primary site, one of the adaptations is epithelial to mesenchymal
transition (EMT), which allows cells to acquire a more mesenchymal phenotype, increasing
their abilities to migrate and invade through the ECM. However, the cancer cells later revert to
the mesenchymal phenotype by mesenchymal to epithelial transition (MET) allowing adherence
to ECM and growth at the metastatic site. This ability of cancer cells to switch between different
phenotypes through EMT and MET is a feature of “epithelial plasticity” [61, 62].
A recent study demonstrated that switching between different modes of cell migration
is required for epithelial plasticity and metastasis [63], indicating the role of migration of cells
in metastasis. In prostate cancer, a number of studies have demonstrated a strong correlation
between increased migration of prostate cancer cells and metastasis [64-66]. However, the
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molecular mechanisms that regulate the process of migration remain unclear. Hence, a principal
focus of this thesis was to understand the role of migration in metastasis of prostate cancer.
Migration signaling in prostate cancer
While there multiple modes of migration, classified as amoeboid migration,
mesenchymal migration, multicellular streaming and collective migration [67], the underlying
process in all the modes of migration results in changes in cytoskeletal dynamics. These are
highly complex processes that involve many signaling pathways [68].
Relevant to my work, Focal Adhesion Kinase (FAK) is a critical mediator of migration
signaling. FAK is a non-receptor tyrosine kinase that localizes to focal adhesions, which
mediate interactions between the extracellular matrix and intracellular signaling through
integrin activation upon cell attachment to the extracellular matrix [69]. The role of FAK in
migration is demonstrated in FAK-null mouse embryonic fibroblasts, which form irregular focal
adhesion complexes in which FAK turnover does not occur and cells do not migrate; the first
demonstration that FAK turnover was essential to migration [70]. The next section of this thesis
briefly describes the structure and activation of FAK followed by the role of FAK in the process
of cell migration.
Focal adhesion kinase (FAK)
Structure of FAK
FAK is a 128 KDa non-receptor tyrosine kinase that, as described above, localizes to
focal adhesions. X-ray crystallography has revealed that FAK consists of an N-terminal fourpoint-one ezrin radixin moesin (FERM) domain, a central kinase domain, proline-rich regions,
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and a C-terminal focal-adhesion targeting (FAT) domain (Figure 1) [71]. These domains are
arranged as a tripartite globular structure with the FERM domain organized in a compact
cloverleaf conformation connected by an unstructured linker to the catalytic domain, which in
turn is connected to a four-helix bundle structure of FAT domain by an unfolded proline-rich
region (Figure 2). Each of these domains and their functions are briefly described below.
N-Terminal domain
The N-terminal is also known as the FERM domain that has three lobes, the F1, F2 and
F3 subdomains. The F1 subdomain consists of a five-strand β sheet capped by and α-helix. The
F2 subdomain is entirely α-helical with a core similar to acyl-CoA-binding protein. This region
of the protein docks with the catalytic domain of the FAK itself and forms the auto-inhibited
conformation. The F3 subdomain is a β-sandwich capped by a C-terminal α-helix. The linker
between the FERM and the kinase domain consists of an anti-parallel β-sheet that binds on a
groove on the F3 subdomain. Two important features of the linker are tyrosine 397, the major
autophosphorylation site and the nearby “PxxP” motif that acts as and SH3-domain binding site
[72] as shown in Figure 2. The FERM domain facilitates interaction of FAK with other receptor
tyrosine kinases such as MET, EGFR, PDGFR and also some integrins [73]. These interactions
are required to activate signaling cascades that promote migration, as well as invasion, survival,
proliferation, adhesion and anti-apoptosis[73].
Kinase domain
This is the primordial conserved domain related to all tyrosine kinases. The crystal
structure of FAK kinase domain reveals a bilobed structure with the N-terminal lobe containing
a single α-helix with a five-stranded β-sheet and the larger C-terminal lobe that is mostly α- 11 -

helical [72]. In the kinase domain itself are three tyrosine phosphorylation sites (Y407, Y576
and Y577). Phosphorylation of these sites results in formation of a β hairpin loop confirmation,
as observed in other active kinases [74].
C-Terminal domain
The C-terminal of FAK contains the focal adhesion targeting (FAT) domain contains
four amphipathic α-helices that assemble into an antiparallel four helix bundle. The FAT
domain also consists of two hydrophobic patches that bind to the FAK-associated proteins
containing the leucine-rich (LD) domain. The α- helix 1 of the FAT domain contains tyrosine
861 and tyrosine 925 [75]. Specific functions of the C-terminal domain of FAK include
association of the FAT domain to integrins and localization of FAK to focal adhesion
complexes, which is required for migration of cells [72, 75]. Additionally, tyrosine 861 and
tyrosine 925 upon phosphorylation by Src family kinases (SFKs) recruit Grb2 via the Grb2 SH2
domain, leading to activation of the Ras/Raf/MAPK/ERK proliferation pathway.
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Figure 1: Structure of FAK. FAK consists of an N-terminal FERM domain, a C-terminal
FAT domain and a kinase domain. Multiple tyrosine phosphorylation sites present on FAK
include Y397, Y401, Y576, Y577, Y861 and Y925. FAK contains three proline-rich regions
PRR1, PRR2 and PRR3 that bind to SH3 domain containing proteins.
From Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: In command and
control of cell motility. Nat Rev Mol Cell Biol 6: 56-58. Reproduced with permission.
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B.

A.

C.

D.

Figure 2: Crystal structure of FAK A. Three lobes FERM domain with subdomains F1
(Red), F2 (Blue) and F3 (Green) B. Kinase domain with a small N-terminal lobe with single αhelix and β strands C. FAT domain of FAK with the containing four-helix bundle (colors
indicate different helices) D. Structure of auto-inhibited FAK FERM domain, the FERM
domain is indicated blue, the linker segment is green and the kinase domain is yellow. Tyrosine
397 autophosphorylation residue is on the linker segment represented by sticks colored in red.
Association of p130Cas to the tyrosine 861 and tyrosine 925 leads to recruitment of Crk/DOCK
complexes, that regulate signaling pathways involved in migration of cells [76-78].From Hall
JE, Fu W, Schaller MD. (2011) Focal Adhesion Kinase: Exploring FAK Structure to Gain
Insight into Function. Int Rev Cell Mol Biol. 288-185-225. Reproduced with permission.

- 14 -

Activation and regulation of FAK
As stated above, FAK can be activated by multiple mechanisms, principally including
integrin clustering or growth factor receptor activation [72]. FAK activation occurs through
sequential steps starting with release of the FERM-kinase domain from the intramolecular
interaction after binding to a heterologous FERM binding partner. After the FERM domain is
released, activation of FAK occurs upon autophosphorylation of tyrosine 397 [79].
Phosphorylated tyrosine 397 then binds to SH2-domain containing proteins including Src
family kinases (SFKs), PI3-Kinase, PLCγ, SOCS, Grb7, Shc and p120RasGAP. SFK binding
to pFAK Y397 (through the SFK SH-2 domain) leads to activation of the interacting proteins
(Figure 4), and phosphorylating each of the other tyrosine phosphorylation sites on FAK,
specifically Y577, Y576, Y407, Y861 and Y925 [80]. As stated above, phosphorylation of FAK
Y576 and FAK Y577 is required for complete activation of the FAK kinase, and the activated
FAK kinase domain adopts a conformation that cannot be inhibited by FERM-mediated
intramolecular interactions, as the phosphorylated activation loop precludes the inhibitory
docking of the FERM domain (Figure 2) [80].
Role of FAK and cell migration
For migration to occur, the leading edge of the cells must attach to the ECM, a process
that results in formation of focal contacts [81]. During the formation of focal contacts, FAK is
recruited to the focal contacts and associates with the Arp2/3 complex to promote actin
polymerization and causes cell spreading [82]. The cell then elongates to form cell protrusions
called pseudopods, which result in distinct polarity differences between the cell “front” and
“rear” as shown in Figure 4 [83]. The cell protrusions that associate with ECM are called
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lamelipodia, which are broad, flat sheet like structures and filopidia, which are thin, elongated,
needle-like structures [84]. In the next stage of migration, the growing protrusions containing
integrins bind to the ECM resulting in integrin clustering leading to autophosphorylation of
FAK Y397 and subsequently phosphorylation of FAK at Y401, Y576, Y577, Y861 and Y925
[85]. Specific to migration signaling, phosphorylation of FAK Y397 leads to recruitment of PI
3-kinase and activation of Rac GTPases required for lamelipodia formation and migration
(Figure 5) [86]. Phosphorylation of FAK Y 861 and FAK Y 925 leads to recruitment of p130Cas
and formation of complexes with Crk/DOCK 180 and activation of Rac GTPases, which are
also essential in lamelipodia formation, and cell migration [87]. Simultaneously, FAK
phosphorylates both the guanine nucleotide exchange factor (GEF), that activate Rho proteins
and GTPase activating protein (GAP) that deactivate Rho proteins necessary to generate
contractile forces and induce cell polarity required for migration [88]. In the final stages of
migration, tyrosine phosphorylation of FAK results in disassembly of focal adhesion complexes
[89], detachment of the trailing edge leading to turnover of FAK and forward movement of the
cell.
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Figure 3: Activation of FAK. The FERM domain directly binds to the kinase C-lobe when
FAK is auto-inhibited, impeding access to the FAK active site and protecting FAK activation
loop from phosphorylation by SFKs. Binding of a protein or a lipid-partner to the FAK FERM
domain leads to conformational change in FAK and release of the auto-inhibited “closed” state.
This conformational change allows binding of SFKs leading to tyrosine phosphorylation of
FAK and increases its kinase activity.
From Frame MC, Patel H, Serrels B, Leitha D, Eck MJ (2010). The FERM domain: organizing
the structure and function of FAK. Nat Rev Mol Cell Biol.11 (11):802-14. Reproduced with
permission.
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Figure 4: Cell migration. Directed cell migration occurs upon coordinated formation of focal
adhesion complexes in the leading edge of the cell followed by simultaneous detachment of the
focal complexes in the trailing edge of the cell. Several molecules like integrins, FAK, Rho/Rac
GTPases are required for the cell to migrate.
From Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: In command and
control of cell motility. Nat Rev Mol Cell Biol 6: 56-58. Reproduced with permission.
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FAK in prostate cancer progression
FAK is overexpressed in many solid tumors; including prostate cancer and increased
FAK expression is associated with prostate cancer progression [90, 91]. However, the existing
studies on FAK overexpression and prostate cancer are correlative; and whether overexpression
of FAK plays a casual role of FAK in prostate cancer progression still remains to be established
[92].
In addition to lack of knowledge about the role of FAK overexpression in mediating
prostate cancer metastasis, considerable information is lacking with respect to potential roles of
differential phosphorylation of different FAK tyrosine residues. While FAK phosphorylation
and the signaling pathways mediating proteins interacting with these tyrosine residues have
been well described, few studies have addressed whether altered phosphorylation at one or more
sites contribute to tumorigenicity and progression of prostate cancer. Recent work from Slack
JK et al. has indicated that phosphorylation of FAK Y861 is associated with more migratory
prostate cancer cells [78]. Additionally, phosphorylation of FAK Y861 is also associated with
oncogenic transformation of fibroblasts [93]. However, these observations are only
associations, and mechanisms of increased phosphorylation of specific FAK tyrosine
phosphorylation sites and their biological relevance is unclear. Hence, this thesis focused on the
unanswered questions in FAK regulation that might mediate biological properties of prostate
cancer progression.

- 19 -

Figure 5: FAK is the central mediator of migration pathway. Multiple molecular pathways
regulate migration of cells including integrins and growth factor receptors and non-receptor
tyrosine kinases. The FAK/SFK signaling pathway is the central mediator of migration
signaling. Additional pathways that regulate migration, survival and proliferation of cells
include, PI3-K /AKT and the Ras/Raf/MEK/ERK pathway.
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Src family kinases- Structure, Activation and Function
As discussed in the previous sections, after the initial autophosphorylation of FAK,
SFKs are required for the additional phosphorylations. These phosphorylations are critical to
all FAK functions, including migration, invasion, angiogenesis, cell survival, cell proliferation,
cell cycle regulation, epithelial to mesenchymal transition and resistance to anoikis [94-99]. As
SFKs are required for FAK-mediated migration, it is not surprising that Src family members
themselves are also associated with migration, as activation of Src increases migration [100103] and src-/- cells are impaired in migration [104]. Therefore, understanding the relationship
among SFKs and FAK is critical in understanding the migration process.
Structure and activation of the SFK family
SFKs are a group of nine structurally highly related non-receptor tyrosine kinases
consisting of Src, Yes, Fyn, Lyn, Lck, Blk, Fgr, Yrk and Hck [100]. SFKs mediate signals from
numerous cellular stimuli including integrins, receptor tyrosine kinases, cytokine receptors, ion
channels, G-protein coupled receptors, polypeptides, and hormones that activate downstream
signaling pathways that regulate numerous cellular functions. To better understand the role of
SFKs in prostate cancer migration, a brief introduction to the structure and activation of SFKs
are described below.
The structure of SFKs is composed of an N-terminal membrane-targeting region that is
myristoylated. Many Src family kinases (the exception being Src itself) are also palmitoylated
at the N-terminal glycine residue. The Src homology-4 (SH-4) domain residues at the amino
terminus function for membrane localization; Src homology-3 (SH3) domain involved in
intermolecular binding by recognizing prolines in the Pro-xx-Pro motif of the substrates; the
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Src homology-2 (SH2) domain interacts with numerous phospho-tyrosine containing proteins,
including its own C-terminal tyrosine 530 residue that leads to a closed conformation (see
below); the kinase domain or Src homology-1 (SH-1) is the primordial tyrosine kinase domain
[105].
Activation of SFKs occur when the SFK-SH2 domain of FAK has higher affinity to the
phospho-tyrosine domains of numerous factors that it can interact with relative to the negativeregulatory tyrosine 530 (human nomenclature) residue on its own SH2 domain [100]. Upon
binding of the activated growth factor receptors to SFK-SH2 domain, a conformational change
occurs that increases the accessibility to phosphatases that dephosphorylate the C-terminal
phospho-tyrosine residue (tyrosine 530 in human Src). Once in the “open” conformation,
autophosphorylation of the tyrosine 419 residue (human Src) occurs leading to “complete”
catalytic activation of Src (Figure 6) [106].
As numerous proteins that interact with SFKs are aberrantly expressed or activated in
several solid and hematological tumors [107-110], SFKs themselves are also frequently
activated as well [110, 111].
SFKs in Prostate cancer
SFKs have aberrantly increased activity in prostate cancer cells and they have various
functions in prostate cancer progression as described above. Additionally, different members of
the SFK family are also suggested to play important roles in prostate cancer progression. Jensen
AR et al., demonstrated that Fyn plays important roles in prostate cancer cell growth and
chemotaxis, required for metastasis [112]. Additionally, Lyn kinase regulates androgen
expression and activity in castrate-resistant prostate cancer and mice in which Lyn is
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functionally deleted showed abnormal morphogenesis of the prostate gland [113-115].
Interestingly, a recent study by Cai H et al. indicates that ectopic expression of Src, Fyn and
Lyn kinase in primary prostate cancer cells isolated from Src−/−Fyn+/−, Fyn+/−, Fyn−/−, or
Lyn−/− knockout mice have different transformation capacities, with Src inducing the strongest
oncogenic phenotype, followed by Fyn and then Lyn [116]. Regenerated tissue from Lyn-/epithelium on transformation displayed neoplastic growth, whereas transformation of tissues
from Fyn-/- epithelium exhibited PIN lesions. In contrast, transformation of tissue from
Src−/−Fyn+/− mice resulted in normal glandular structures [116]. These data strongly suggest
that different SFK members have different roles in mediating prostate cancer progression.
Understanding these roles may be of critical importance because of the recent failure of
an SFK inhibitor, Dasatinib in an international phase-3 clinical trial [117]. Numerous
investigators have suggested that this failure may be due to lack of understanding of specific
and overlapping roles of SFKs in tumor progression and bone metastasis [118-120]. Strikingly,
there have been no studies published on specific roles of Yes in these processes; the work in
my thesis has provided an understanding of some of its critical functions.
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Figure 6: Structure and activation of SFKs. In an inactive status, SFKs are in a "closed"
conformation by intramolecular interactions between SH-3 domain and Pro-X-X-Pro domain
and between SH-2 domain and negative regulatory phosphorylated tyrosine 527 residue. This
closed conformation limits accessibility of the kinase domain active site for substrates. SFKs
attains a more "open" conformation through phosphatase-mediated dephosphorylation of the
Y527 residue and higher affinity of SH-2 and SH-3 domains to activated binding partners and
also through phosphotyrosine residues and Pro-X-X-Pro motifs. Further phosphorylation at
tyrosine 416 in SH-1 kinase domain is required for “complete” kinase activity of SFKs, leading
to open accessibility of substrates to the active binding sites of the kinase domain.
From Yeatman TJ (2004) A renaissance of SRC. Nat Rev Cancer 4(6):470-480. Reproduced
with permission.
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Differential roles of Yes kinase in regulating cellular signaling
Since, Src and Yes kinase are the two most structurally similar members with about 90%
structural homology, there are signaling and functional redundancies in between these two
kinases[121]. However, there are also specific structural and functional differences between
Yes and Src kinase indicating a possibility of different roles in tumor progression [121, 122].
These structural differences suggest the possibility of different roles and indeed a previous study
from our lab has indicated that Yes activation portends poorer survival in colorectal metastases
than does Src activation [123]; however, these correlative studies have not defined specific roles
for Yes. As indicated above, a potential role for Yes activation in promoting prostate cancer
progression or metastases was unknown before the work performed in my thesis.
Summary of problems and hypothesis
Prostate cancer is the second leading cause of cancer-related deaths in men in the Unites
States [1]. Although, the five-year survival rate of patients with early-stage disease is ~99%,
the survival rate of patients with metastatic disease including to the lymph node and bones,
drastically decreases to 31% [124]. Thus, understanding the molecular mechanisms that drive
prostate cancer metastasis could lead to development of novel therapeutic strategies to prevent
metastasis.
The goal of this PhD. thesis was to focus on specific aspects of migration, an early step
in the metastatic cascade [81]. One of the mediators of migration of cells is FAK [85].
Additionally, FAK is overexpressed in prostate cancer [91, 125]. However, whether FAK has a
role in increased metastasis of prostate cancer remains unknown. FAK is phosphorylated by
SFKs and SFK-mediated FAK phosphorylation is one of the mechanisms that regulate
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migration of cells [94, 106]. SFKs also regulate numerous biological properties that promote
metastasis of prostate cancer including migration of cells and increased SFK activity is
associated with prostate cancer progression [100, 106]. However, a novel small molecule
inhibitor of SFK has failed to show significant improvement in overall survival in patients with
metastatic castrate resistant prostate cancer [117], indicating the need for a deeper
understanding of the molecular mechanisms that are regulated by different SFK members.
Current knowledge implicates, Src (a member of the SFK) as the major kinase that
phosphorylates FAK [126]. However, recent evidence indicates that different SFK members
have different role in prostate cancer progression [113, 116, 127]. Hence, the emphasis was to
understand if specific changes in the FAK-SFK complexes could be identified that promote
migration and affect important processes of metastasis.
Recent studies have demonstrated increased phosphorylation FAK Y861 in migration
of prostate cancer cells [78]. However, the cause and effect of this phenomenon is still unclear.
Therefore, the first question addressed in this dissertation is whether all the tyrosine residues on
FAK are phosphorylated equally in the PC3 Mig-3 and DU145 Mig-3 cells and specifically
understanding the role of increased phosphorylation of FAK Y861 in highly migratory prostate
cell models, which were developed by me. The second question was what is the association of
increased phosphorylation of FAK Y861 in survival of patients? The third question was what
is the mechanism of increased phosphorylation of FAK Y861, leading to understanding the
roles of Yes kinase in preferential phosphorylation of FAK Y861? In addition, the fourth
question was whether Yes kinase promotes prostate cancer metastasis and if increased Yes
expression is associated with prostate cancer progression in patients.
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The hypothesis tested in this dissertation was that changes in the FAK/SFK complexes
dictate the increased migration in prostate cancer cells and promotes prostate cancer metastasis.
To test this hypothesis, I first isolated highly migratory variants of prostate cancer cells named
PC3 Mig-3 and DU145 Mig-3 from parental PC3 and DU145 cells. I then examined the role of
pFAK Y861 in migration of these cells by overexpressing its non-phosphorylatable form FAK
Y861F in the PC3 Mig-3 cells and then investigated the relevance of pFAK Y861 expression
with survival of prostate cancer patients. Then, I investigated the mechanism of increased
phosphorylation of FAK Y861 by silencing Yes in PC3 Mig-3 and overexpressing Yes kinase
in parental PC3 cells. Finally, I assessed the role of Yes kinase in prostate cancer metastasis in
vivo and investigated the clinical relevance of Yes expression in matched primary tumor and
lymph node metastasis from patients. Together, this work addressed the mechanism and
biological function of FAK Y861 phosphorylation and providing a better understanding of the
mechanism for prostate cancer metastasis.
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Chapter-2
Materials and Methods
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Cell culture
Human prostate cancer cells lines; PC3 cells were a gift from Dr. Isaiah J. Fidler’s
laboratory and were maintained in DMEM F-12 (Hyclone) supplemented with 10% FBS
(Hyclone). DU145 cells were a gift from Dr. Renata Pasqualini’s laboratory and were
maintained in RPMI 1640 (Corning cell gro) supplemented with 10% FBS (Hyclone). SYF
(Src-/-, Yes-/-, Fyn-/-) mouse embryonic fibroblasts were bought from ATCC and grown in
DMEM media containing 10% FBS, glutamine and pyruvate. Cell cultures were incubated in
5% CO2/95 % air tissue culture incubators at 37oC. Cells were checked every three months to
be mycoplasma free. Fingerprinting analysis was performed on these cell lines by the M.D
Anderson Cancer Center Department of Systems Biology and the identities of these cell lines
were confirmed. The analysis was performed using the AmpF_STR Identifier kit according to
the manufacturer’s instructions (Applied Biosystems #4322288). The STR profiles were
compared to known ATCC DNA fingerprints (ATCC.org) and to the cell line integrated
molecular
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Migration assay
Migration abilities of the PC3 and DU145 cells were determined by the modified
Boyden chamber migration assay as described by Lesslie et al. [98]. Briefly, PC3 and DU145
cells were trypsinized and plated (0.05 X 106) in the upper well of the 8.0µm pore size
polyethylene terephthalate membrane culture inserts for 24 well plates (BD Biosciences,
Medford MA) in 500µL DMEM/F12 media without FBS. The lower chamber was filled with
750µLof DMEM/F-12 supplemented with 10% FBS as a chemo attractant. After 24 hours, the
non-migratory cells from the upper chamber were scraped using a cotton swab. The cells that
had migrated in the lower chamber were fixed and stained with HEMA-3 stain kit (EMD,
Millipore) according to the manufacturer’s protocol. Migrated cells were counted in 100X
magnification under the microscope in five random fields/inserts in triplicates. Each experiment
was performed in triplicates.
Time-lapse microscopy and quantification of cell migration
Subconfluent tumor cells were detached with 2mM EDTA (Ambion #AM9260G),
embedded (33,000/100 μl) in bovine collagen (PureCol, Advanced BioMatrix, Catlog #5005B; final concentration 1.7 mg/ml), and afterwards incorporated into a self-constructed chamber.
To construct the migration chamber an object slide and a coverslip were connected by a spacer
composed of vaseline / paraffin (1:1), resulting in an approximate chamber size of 20 x 20 x 0.5
mm and a volume of ~200 μl. After addition of medium, spontaneous migration was monitored
by digital time-lapse, bright-field inverse microscopy (air objectives, 10×, NA 0.20; Leica) at
37°C using CCD cameras (Sentech) and the 16-channel frame grabber software (Vistek) for 24
hr. with 4-min frame intervals. Migration speed was quantified by computer-assisted cell
tracking (Autozell 1.0 software; Centre for Computing and Communication Technologies
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[TZI], University of Bremen, Bremen, Germany) of xy paths with 12-min step intervals (tumor
cells). The average speed per cell was calculated from the length of the path divided by time,
including “go” and “stop” phases.
Invasion assay
Invasion abilities of the PC3 and DU145 cells were determined by the modified Boyden
chamber invasion assay as described by Lesslie et al.[98]. . Briefly, parental PC3 cells (0.5 X
106) were suspended in the upper well of the 8.0µm pore size polyethylene terephthalate
membrane culture inserts for 24 well plates coated with matrigel (BD Biosciences) in 500µL
DMEM/F12 media without FBS. The lower chamber was filled with 750µLof DMEM/F-12
with 10% FBS as a chemo-attractant. After 24 hours, the non-invasive cells from the upper
chamber were scraped using a cotton swab. The cells that had invaded in the lower chamber
were fixed and stained with HEMA-3 (Biochemical Sciences) according to the manufacturer’s
protocol. Invasive cells were counted in 100X magnification under the microscope in five
random fields/inserts in triplicates.
Adhesion assay
PC3 and DU145 cells (5 X 104 cells/ 100µL) were seeded into each well of a 96 well
plate. The plates were incubated for 30 minutes in 37oC; the wells were washed with PBS three
times and incubated with 1µmol/L Calcein AM (Invitrogen Life Technologies, Grand Island,
NY, USA) for 3 minutes. The cells that adhered to the plate were quantified by measuring the
fluorescence intensity at 458/528 nm in each well on a Synergy HT fluorescent plate reader
(BioTeK).
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Proliferation assay
3 x 104 cells / well were cultured in 6-well dishes for up to 96 hours. For cell counting,
at various time points, the media was removed, cells were washed with once PBS (Gibco), and
500µl TrypLE dissociation reagent (Gibco) was added to each well. Cells were then incubated
for 5 minutes at 37ºC. Complete media (1ml) was then added to each well, and cells were
resuspended with a micropipette. 500µl cell suspension was transferred into a separate cup
(Beckman Coulter) and cells were counted using an automated cell viability analyzer Vi-Cell
XR (Beckman Coulter). All experiments were performed in triplicate.
Immunoblotting
Clarified cell lysates (50µg/lane) were separated by SDS-PAGE on 8% gels and
electroblotted onto PVDF (Immobilin-P) membranes (EMD Millipore, Billerica, MA,USA) as
described previously(). Membranes were blocked with 5% skimmed milk in TBS-T and
incubated with primary antibodies (listed in table) overnight at 4oC. All mouse monoclonal
antibodies were followed by horseradish peroxidase-conjugated rabbit anti-mouse IgG (ICN
Biochemicals Inc., Costa Mesa, CA, USA); rabbit polyclonal antibodies were followed with
horseradish peroxidase conjugated goat anti-rabbit IgG. Specific binding was determined using
the Pierce ECL western blotting substrate (Thermo Fisher Scientific, Waltham, MA, USA).
Immunoprecipitation
Cells were rinsed with ice cold PBS, then detergent lysates were made in a standard
Radio Immuno Precipitation Assay ‘A’ buffer (Garcia et.al 1991). Cells were homogenized and
clarified by centrifugation at 10000g. Cell lysates (500 µg protein) were reacted for 12 hours
with the monoclonal antibody for anti-Src (Cell Signaling Technologies, Inc., Danvers,
- 32 -

MA,USA), Yes, Fyn and Lyn (Santa Cruz Biotechnology, Dallas, TX,USA). The next day,
50µL of 1:1 slurry of protein ‘A’ or protein ‘G’ agarose beads (Millipore) in NP-40 buffer was
added to the protein lysate- antibody mixture and incubated for an additional 2 hours in 4oC.
Bound proteins were pelleted by centrifugation, washed three times with Np-40 buffer, and
eluted by boiling in 1X Lamelli’s sample buffer. Bound proteins were subjected to western blot
analysis as described above.
RNA isolation and quantitative RT-PCR
RNA was isolated from the cells using RNAeasy™ mini kit (Catalog # 74104, Qiagen,
Valencia, CA, USA) according to the manufacturer’s instructions. Briefly, total RNA (200ng)
was reverse transcribed by using a cDNA synthesis kit (Invitrogen, Life Technologies, Grand
Island, NY, USA) according to the manufacturer’s instructions. Gene expression was
determined by quantitative PCR (qPCR) using KiCq Start SYBR Green kit (Sigma). The primer
sequences for Yes were forward- TCCTGCTGGTTTAACAGGTGGTG and reverseTGCTTCCCACCAATCTCCTTCC
Rho-A activation assay
Rho-A activation was determined by Rho G-LISA™ assay kit according to the
manufacturer’s instructions (Cytoskeleton Inc., Denver, CO, USA). Samples were prepared
according to the instructions. Briefly, PC3, PC3 Mig-3, and Mig-3 FAKY 861-F cells were
grown in subconfluent conditions for 3 days. The cells were then counted and plated in 12 well
plates in serum-free media overnight. The cells were then stimulated with 10% FBS containing
media and lysates were made from the cells immediately after 0, 6, 12, and 30 minutes. Protein
assay was performed and an equal amount of protein was added to the wells of the Rho G-LISA
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plate coated with Rho-GTP binding protein. The plate was placed in a cold micro plate shaker
at 300rpm at 4oC for 30 minutes. The plate was then washed 3 times with wash buffer at room
temperature. Then anti-Rho an antibody (1:250 dilution) was added to each well and the plate
was placed on the shaker for an additional 30 minutes. After three washes, the horseradish
peroxidase reagent was added to the wells. The luminescence signal from the wells was read
@490 nm using a microplate spectrophotometer. Results are shown as absorbance over the
background signal (background signal is incubation from the assay reagent only).
Lentiviral-mediated pFAK Y861F expression
The FAK Y861F, WT FAK and empty vector plasmids were constructed by Dr. Rebecca
Schweppe’s lab (University of Colorado, USA). These plasmids contain a blasticidin resistant
gene and a gene encoding V5 tagged mutant FAK Y861F. The lentivirus was infected (MOI:
11) into the PC3-Mig 3 cells using 4µg/mL polybrene. After 24 hours of infection, the media
was replaced with DMEMF12 and RPMI 1640 containing 10µg/ml Blasticidin Hcl.
Lentivirus-mediated Yes silencing
Mission shRNA bacterial glycerol stock plasmids for Yes were purchased from SigmaAldrich.

Sequences

used

for

Yes

were

TRCN0000001611:CCGGACCACGAAAGTAGCAATCAAACTCGAGTTTGATTGCTAC
TTTCGTGGTTTTT,TRCN0000010006:CCGGTGGTTATATCCCGAGCAATTACTCGAG
TAATTGCTCGGGATATAACCATTTTT. A non-targeting control was used along with the
shRNA plasmid. The knockdown of Yes using both the sequences was confirmed by
immunoblotting. For lentivirus production, the pLKO.1-puro plasmid (3 µg) was co-transfected
with the packaging plasmid pCMV-dR8.2 dvpr (3 µg) and the envelope plasmid pCMV-VSV- 34 -

G (0.6 µg) in a ratio of 5:5:1 into 293FT cells in one 100-mm plate (Life Technologies) using
Lipofectamine 2000 (Life Technologies). After 24 hours incubation in culture, medium was
replaced with 20% FBS. The viral supernatant was collected after 24 hours and again at 48
hours, filtered through 0.45 µm filters followed by centrifugation at 20,000 rpm for 2 hours at
4 ℃. The viral pellet was resuspended in 200 µl of RPMI medium and stored at -80 ℃. Cells
were cultured in 48-well plates were incubated with 20 µl of virus supernatant in the present of
8 μg/ml of polybrene (Sigma) and centrifuged at 500 ×g for 20 min and further incubated for
24 hr. The medium was changed after 24 hours and replaced again with 5 μg/ml puromycin
after 48 hours and incubated for one week to select stable silenced cells.
Yes kinase overexpression
Yes was transiently overexpressed in the PC3-P cells using the PCMV6-XL5 Yes
overexpression plasmid. (Catalog # SC116734, OriGene Technologies, Inc., Rockville MD,
USA). The negative control was provided by the manufacturer (Catalog # PCMV6-XL5). The
Yes plasmid was sequenced using VP1.5 (forward) 5' GGACTTTCCAAAATGTCG 3' and
XL39 (reverse) 5' ATTAGGACAAGGCTGGTGGG 3'
Src kinase overexpression
Full-length c-Src was cloned in PCDNA3.1 plasmid as described by Trevinio JG et. al.
[128] . 2µg of the plasmid was used to transfect the SYF cells and the PC3 cells using the
jetPRIME (Polyplus-transfection, Illkirch, France) according to the manufacturer’s instructions.
The cells were selected with 100 µg/mL of G418 antibiotic containing DMEMF-12 media
containing 10% FBS. The PC3-Src cells were selected and cultured to get a stable cell line
overexpressing Src.
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Immunohistochemical staining
Immunohistochemistry was performed as described previously. Briefly, paraffin
embedded tissue sections were heated at 65oC overnight before deparaffinization in xylene,
followed by treatment with graded series of alcohols (100%,95%,80% ethanol [vol/vol] in
double distilled H2O) and rehydration with PBS (pH 7.5). For antigen retrieval, tissues were
submerged in 0.1 M EDTA and Citrate buffer for pFAK Y861 and pFAK Y397 respectively in
a pressure cooker for a total of 40 minutes (4 minutes actual cook time). After washing with
PBS endogenous peroxidases were blocked with 3% hydroxyl peroxide (H2O2) in PBS for 12
minutes, followed by three washes in PBS. The sections were blocked with cyto Q background
buster for 30 minutes followed by incubation with the primary antibodies in Immunodiluent
(Innovex) overnight at 4oC. After washing with PBS, the slides were incubated with HRP Mach4 polymer anti-rabbit antibody (Bio care, Concord, CA, USA) for 1 hour. After 3 washes with
PBS the chromogenic reaction was visualized using 3-3’ diaminobenzidine (DAB) solution
(Invitrogen, Life Technologies, Grand Island, NY, USA) for 3 minutes or until good color
formation was observed by monitoring the reaction under the microscope. The sections were
counter stained with Gill’s hematoxylin solution for 1 minute, and mounted with universal
mount (Research Genetics, Inc. AL,USA).
Quantification of immunohistochemical staining
Quantification of immunohistochemical staining for expression of Yes and pFAK Y861
was performed using the NIH ImageJ software. The tumor tissue was scanned under bright field
(magnification 100X, 0.14 mm2) using Sony DXC-990 three chip charged-coupled device color
video camera mounted on Nikon-Microphot-FX microscope (Nikon Co.). Five representative
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images were selected randomly analyzed. Images were then processed and quantified using
Image J, a public domain Java image-processing program (U. S. National Institutes of Health,
Bethesda, Maryland, USA). Briefly, brown-colored images specific for DAB stain were
extracted by the color deconvolution macro, inversed and measured for intensity using NIH
ImageJ internal commands. All intensity values in the group were averaged to calculate
intensity of pFAK Y861 and Yes expression in primary tumors and lymph node metastasis
tissue as described by Park SI et al. [114].
In vivo tumorigenicity assay
PC3-P and PC3 Mig-3 cells were detached from subconfluent cultures and a desired
number of cells were centrifuged and resuspended in Ca2+-free and Mg2+-free HBSS (Life
Technologies, Austin, TX, USA). For implantation of the cells in prostate, the procedure of Kim
et al. was followed. Male athymic nude mice (Ncr nu/nu; ages 8-12 weeks; the National Cancer
Institute-Fredrick Animal Production Area) were anesthetized with pentobarbital sodium i.p
(0.5mg/1gm of body weight; Nembutal (Abbott laboratories, Abbott Park, IL, USA) and placed
in a supine position. A midline incision was made in the lower abdomen and the prostate was
exteriorized. 50µL of HBSS containing 125,000 PC3-P cells and (125,000, 500,000 and 1X106)
Mig-3 PC3 cells were injected to the dorsolateral side of the prostate. The incision was closed
with surgical metal clips (Braintree Scientific, Inc., Braintree, MA, USA).
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Statistics:
Statistical analyses for differences of tumor weight were performed using the GraphPad
Prism software. ANOVA and Tukey’s test was conducted to compare differences in tumor
weight. Incidences of tumors and lymph node metastases were compared between groups with
the Fisher’s exact test. Migratory cell numbers in modified Boyden chamber migration assay
were compared by Student’s t-test. Statistical analysis for pFAK Y861 and Yes
immunohistochemistry was performed using one-way ANOVA and unpaired t-test. P values of
less than 0.05 were considered statistically significant.
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Chapter-3
Biological characterization of PC3
Mig-3 and DU145 Mig-3 cells
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Isolation of PC3 Mig-3 and DU145 Mig-3 subclones from parental cells
50,000 PC3 and DU145 cells (PC3-P and DU145-P) were seeded on the upper chamber
of the Boyden chamber for 24 hours. The cells that migrate through the chamber for 24 hours
were collected from the bottom chamber and grown in culture. This process was repeated for 3
cycles to isolate the more migratory from both PC3 Mig-3 and DU145 Mig-3 cells. The
selection was continued again for one more time to get PC3 Mig-4 cells; however, there was no
further increase in migration in the PC3 Mig-4 cells. Hence, the PC3 Mig-3 and DU145 Mig-3
population from both the cell lines was used for further investigation. The PC3 Mig-3 and
DU145 Mig-3 cells were grown in culture for < 30 passages and the migration abilities for the
cells were found to be consistent.
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Figure 7: Schema for isolation of PC3 Mig-3 and DU145 Mig-3 cells. Modified Boyden
chamber migration assay was used to isolate highly migratory prostate cancer cells. The cycle
of isolation was repeated three times to get a subclone of highly migratory cells. The PC3 Mig3 and DU145 Mig-3 cells were stable for more than 30 passages after multiple free-thaw cycles.
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Morphology
To examine the morphology of the PC3-P, PC3 Mig-3, DU145-P and DU145 Mig-3
cells, equal number of cells were plated in culture overnight and bright field microscopy was
performed to document morphological differences between the cell lines. Bright field
microscopy at 10X magnification indicated no significant changes in morphology in the PC3
Mig-3 cells relative to the PC3-P cells. Similarly, there were no significant morphological
differences observed in the DU145 Mig-3 cells relative to the DU145-P cells. However,
consistent to the literature we observed that DU145 cells were more mesenchymal and PC3
cells were more epithelial (Figure 8).
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Figure 8: Morphology of PC3 and DU145 cells. Morphology of PC3 Mig-3 and DU145 Mig3 cells were compared to PC3-P and DU145-P cells after examination under a light microscope.
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Migration
To examine whether PC3 Mig-3 and DU145 Mig-3 have increased migration relative to
the parental cells, I performed an in vitro Boyden chamber migration assay for 24 hours. As
shown Figure 7, PC3 Mig-3 had 94% (p<0.0001) increase in migration of PC3-P cells.
Consistently, DU145 Mig-3 cells had an 83% (p<0.0001) increase migration field in DU145-P
cells (Figure 9). The increase in migration of the PC3 Mig-3 and DU145 Mig-3 cells were stable
for more than 30 passages with repeated freeze-thaw cycles. To test the increased migratory
abilities of the PC3 Mig-3 using a second assay, we used time-lapse microscopy to determine
the speed of migration after plating them on the cell culture plate.
Time-lapse microscopy was performed on the PC3 Mig-3 cells and the data was
quantified using the Auto Zell software. The speed of migration was calculated by dividing the
distance travelled by a cell from point “A” to “B” divided by the time required to do so. On
comparing the speed of migration within the two groups, PC3 Mig-3 had an increased migration
speed of 0.170µm/min relative to 0.078µm/min in PC3-P cells (2-fold increase) 24 hours after
plating the cells al PC3 cells consistent with the Boyden chamber assay data (Figure 10). To
further characterize the molecular changes associated with migration in PC3 Mig-3 cells, we
performed a DNA microarray using the Illumina platform. On performing an Ingenuity pathway
analysis using the data, I observed that migration and motility pathways were the most
differentially altered pathways at the mRNA levels (Figure 52). These data confirmed that PC3
Mig-3 and DU145 Mig-3 cells had increased in vitro migration relative to the parental cells.
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Figure 9: Migration assay of PC3 Mig-3 and DU145 Mig-3 cells. Migration assay was
performed for 24 hours. Pictures were taken of migrated cells after fixation and staining. The
cells were counted at 20X magnification. Graph illustrates number of cells that have migrated.
Bars represent the average number of cells migrated from triplicate wells. *p<0.002, **
p<0.0002, ***p<0.0001 by Student’s t-test, compared to the control group. Representative
images are used to show the number of cells migrating per field.
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Figure 10:Time-lapse microscopy to determine speed of migration. PC3-P and PC3 Mig-3
cells were plated in bovine albumin containing chamber as described in the materials and
methods. Spontaneous migration was recorded using time-lapse microscopy at 10X
magnification and the speed of migration was calculated using the Auto Zell software.
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Invasion
Invasion of cell through the extracellular matrix is crucial for metastasis to occur. Since,
PC3 Mig-3 and DU145 Mig-3 cells had increased migration in vitro, I further investigated
whether, the in vitro selection for migration, selects for cells with increased invasive properties.
To test this hypothesis, I performed an in vitro invasion assay using a modified Boyden
chamber, coated with matrigel. As shown in Figure 10, PC3 Mig-3 cells had 95% (p<0.0001)
increase in invasion relative to PC3-P cells. Consistently, DU145 Mig-3 cells had a 70%
(p<0.0001) increase in invasion compared to DU145-P cells (Figure 11) correlating with the
increased migration in both cell models.
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Figure 11: Invasion assay of PC3 Mig-3 and DU145 Mig-3 cells. Invasion assay was
performed for 24 hours. Pictures were taken of migrated cells after fixation and staining. The
cells were counted at 10X magnification. Graph illustrates number of cells that have migrated.
Bars represent the average number of cells migrated from triplicate wells. *p<0.002, **
p<0.0002, ***p<0.0001 by Student’s t-test, compared to the control group. Representative
images are used to show the number of cells invading per field.
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Proliferation
To determine whether increased migration and invasion were due to differences in
proliferation; I examined the proliferation rates of PC3 Mig-3 and DU145 Mig-3 cells relative
to the parental cells. Viable cells were enumerated as described in materials and methods. As
shown in Figure 12, the doubling time for PC3-P cells was 19 hours relative to 22 hours for
PC3 Mig-3 cells. The doubling time for DU145-P cells was 19 hours and for DU145 Mig-3
cells, 24 hours. These data are consistent with more migratory cells having reduced proliferation
rates [129].
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Figure 12: Proliferation of PC3 and DU145 cells. PC3-P, PC3 Mig-3, DU145-P, and DU145
Mig-3 cells were plated 5X104 and cultured for indicated times. The cells were then stained
with tryphan blue and counted. *p<0.005 by Student’s t-test, compared to the control group.
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Adhesion
Another property of a more metastatic cell is its ability to detach from the primary tumor
site and enter the circulation. Adhesion was determined by plating 5 X104 cells in each well of
a 96-well plate and washing with PBS after 30 minutes. The number of viable cells bound to
the cell culture plate was determined using Calcein AM staining as described in the materials
and methods. As shown in Figure 13, our results demonstrate that PC3 Mig-3 cells had a 33%
decrease in adhesion relative to PC3-P cells (p<0.005). Likewise, DU145 Mig-3 cells had a
63% decrease in adhesion relative to DU145-P cells (p<0.003). These results indicate that PC3
Mig-3 and DU145 Mig-3 have decreased adhesion relative to the parental cells.
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Figure 13: Adhesion assay of PC3 and DU145 cells. PC3-P, PC3 Mig-3, DU145-P, DU145
Mig-3 cells were plated 50 X 104 for 30 minutes and washed with PBS. The cells were stained
with Calcein AM and fluorescence intensity was measured indicating the viable cells remaining
on the plate. The graph represents average fluorescence intensity of triplicates. *p<0.005 by
Student’s t-test, compared to the control group.
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PC3 Mig-3 cells are more metastatic to the lymph node relative to the parental cells in the
prostate cancer spontaneous metastasis model
Because of the differences in growth rate, we first examined tumor growth in vivo. We
performed an in vivo tumorigenicity assay using the orthotopic nude mouse model. 500,000
PC3-P and 500,000 PC3 Mig-3 cells were orthotopically implanted in the prostate of nude mice
as described in the methods. The tumors were allowed to grow for 4 weeks and the mice were
sacrificed to evaluate the incidence of lymph node metastasis and size of the primary tumor. As
shown in Figure 14, PC3 Mig-3 cells were found to form significantly smaller primary tumors
relative to parental PC3 cells (p<0.0006); however the number of lymph node metastases was
similar. The slow in vivo growth rate of the PC3 Mig-3 was consistent with the in vitro results
and further confirmed with Ki67 staining, which is a marker for cellular proliferation. PC3 Mig3 tumors had significantly less Ki67 positive cells relative to the parental primary tumors,
represented in Figure 15.
To perform metastasis assays, it was desirable to measure metastasis when primary
tumors were of similar size. Therefore a titration experiment was performed. To accurately
examine in vivo tumorigenicity, an increasing number of PC3 Mig-3 and PC3-P cells were
intraprostatically implanted in the nude mice, which were then sacrificed after 4 weeks to
evaluate the size of the primary tumors and incidence of lymph node metastases. All mice
developed primary tumors; however due to differences in proliferation rates, similar sized
primary tumors were obtained implanting 125,000 PC3-P cells and 500,000 PC3 Mig-3 cells
(Table 1). Lymph node metastases were assessed by identifying solid, opaque and enlarged iliac
lymph nodes as represented in Figure 18.
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As shown in Figure 16, similar sized primary tumors were obtained from 125,000 PC3P cells and 500,000 PC3 Mig-3 cells. Additionally, the PC3 Mig-3 tumors formed 4.1±0.3
lymph node metastases relative to 1.5±0.29 lymph node metastases in PC3-P (p<0.005) tumors
as shown in Figure 17. These data, collectively, indicate that PC3 Mig-3 cells are significantly
more metastatic to the lymph node relative to PC3-P cells.
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Figure 14: In vivo growth of PC3-P and PC3 Mig-3 cells. 500,000 PC3-P and 500,000 PC3
Mig-3 cells were injected intraprostatically. The tumors were grown for 4 weeks and the tumor
weight was determined after sacrificing the mice. *p<0.005 by ANOVA and Tukey’s test,
compared to the control group.
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Table 1: Average tumor weight and incidence of lymph node metastasis
*ANOVA and Tukey’s test, PC3 Mig-3 compared to PC3-P, *p<0.005
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Figure 15:Ki67 staining on PC3-P and PC3 Mig-3 tumors. Ki67 staining in fixed sections
from the primary tumors from the PC3-P and PC3 Mig-3 cells. *p<0.005 by Student’s t-test,
compared to the control group.
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Figure 16: Tumor weight of PC3-P and PC3 Mig-3 cells. Variable amounts of PC3 Mig-3
cells (125000, 250000 and 500000) and 125,000 PC3-P cells were injected intraprostatically in
the nude mice. The tumors were grown for 4 weeks and the tumor weight was determined after
sacrificing the mice. *p<0.05, ** p<0.005 by ANOVA and Tukey’s test, compared to the
control group.
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Figure 17: Incidence of lymph node metastasis of PC3-P and PC3 Mig-3 cells. Variable
amounts of PC3 Mig-3 cells (125000, 250000 and 500000) and 125,000 PC3-P cells were
injected intraprostatically in the nude mice. The tumors were grown for 4 weeks and the
incidence of metastasis was determined after sacrificing the mice. ** p<0.005 by ANOVA and
Tukey’s test, compared to the control group.
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Group

Average Tumor
wt. (mg)/ range

Incidence
of
primary
tumor

Average
incidence of LN
mets/ range

Incidence of LN
Metastases

PC3-P (125,000)

598.5 (220-875)*

9/9

1.8 (1-3)**

9/9

PC3 Mig-3 (125,000)

183.1 (45-349)

7/7

2.7(2-4)

7/7

PC3 Mig-3 (250,000)

339.5 (204-490)

7/7

2.6(1-3)

7/7

PC3 Mig-3 (500,000)

423.5 (303-730)*

7/7

4.1( 3-5)**

7/7

Table 2: Average weight of primary tumor and lymph node metastases following
different numbers of PC3 Mig-3 cells injected intraprostatically
ANOVA and Tukey’s test, PC3 Mig-3 compared to PC3-P, *p<0.005, **p<0.001
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Figure 18: Tumor weight and incidence of lymph node metastasis of PC3-P and PC3 Mig3 cells. Representative images of the primary tumors and lymph node metastasis isolated from
after intraprostatic injections.

- 61 -

Chapter-4
Molecular characterization of FAK in
PC3 Mig-3 and DU145 Mig-3 cells
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Increased expression of pFAK Y861 is associated with increased migration in PC3 Mig-3
cells
To examine the role of FAK in increased migration of PC3 Mig-3 and DU145 Mig-3
cells, levels of FAK expression and phosphorylation were determined by immunoblotting as
described in material and methods. As shown in Figure 19 and 20, total levels of FAK
expression in PC3 Mig-3 and DU145 Mig-3 cells were similar. However, in both the PC3 Mig3 and DU145 Mig-3 cells, there was no increase in FAK Y397 phosphorylation (the
autophosphoryation site) and there was no increase in phosphorylation of the SFK-dependent
phosphorylation sites FAK Y401, FAK Y577, FAK Y576 and FAK Y925). In contrast, in both
PC3 Mig-3 and in DU145 Mig-3, an increase in pFAK Y861 expression was observed relative
to the cognate parental cell lines.
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Phosphorylation of FAK Y861 is critical to migration
To determine if pFAK Y861 increases were likely the most important alterations to
migratory potential, I examined two additional proteins known to promote prostate cancer cell
migration and overexpressed during tumor progression, Met and Axl [130, 131]. Roles of Axl
and Met were potentially important as in my uncloned population of Mig-3 cells (both PC3 and
DU145), were increased in expression of these proteins (as well as Yes, discussed below). To
examine if Axl and/or Met to contributed to migration, single cell cloning of PC3 Mig-3 was
performed and individual cell lines were isolated. Expression of key proteins under
investigation from five clones is shown in (Figure 21). Each clone consistently overexpressed
Yes and FAK pY861. However, Met and Axl were variably expressed with some clones
overexpressing both proteins, some failing to overexpress either protein, and other clones
overexpressing either Met or Axl but not both. To determine the potential contribution of Met
and Axl to subclones of PC3 Mig-3 cells, representative examples were chosen in which Met
and/or Axl were overexpressed (see Figure 21 with differential expression of these proteins),
and migration assays were performed as previously described. As shown in Figure 21, neither
increased expression of Met, nor Axl nor both led to increase in vitro migration of PC3 Mig-3
clones relative to parental cells. Importantly, the only consistent alteration that correlated with
increased migration in all of the clones of PC3 Mig-3 cells was increased levels of pFAK Y861
(Figure 22). The significance of Yes kinase in PC3 Mig-3 cells will be discussed in the next
chapter. These results indicated that increased expression of pFAK Y861 is independent of Axl
or Met expression and is most associated with increased of PC3 Mig-3 cells by the selection
procedure used.
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Figure 19: Phosphorylation of FAK in PC3 cells after migration selection. PC3-P, PC3
Mig-1, PC3 Mig-2, PC3 Mig-3 cells were grown in culture. The cells were lysed and subjected
to immunoblot analysis to determine expression of pFAK Y861, pFAK Y397, pFAK Y577,
pFAK Y401, pFAK Y576, pFAK Y925 and total FAK expression. Relative expression was
determined after normalization against total FAK expression using NIH ImageJ.
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Figure 20: Phosphorylation of FAK in DU145 cells after migration selection. DU145-P,
DU145 Mig-1, DU145 Mig-2 and DU145 Mig-3 cells were grown in culture. The cells were
lysed and subjected to immunoblot analysis to determine expression of pFAK Y861, pFAK
Y397, pFAK Y577, pFAK Y401, pFAK Y576, pFAK Y925 and total FAK expression. Relative
expression was determined after normalization against total FAK expression using NIH
ImageJ.
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*

*

*

Figure 21: Expression of proteins involved in migration after subcloning in PC3 Mig-3
cells. PC3 Mig-3 cells were subjected to single cell cloning and subpopulations of PC3 Mig-3
cells were grown in culture. The clones were lysed and the protein was subjected to immunoblot
analysis for expression of Met, Axl, Yes and pFAK Y861.
* indicate the clones used for migration assay
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Figure 22: Migration of the clones of PC3 Mig-3 cells. Specific subclones of PC3 Mig-3
cells, which had differential expression of Axl, and Met, were tested for migration abilities
using a modified Boyden chamber. The cells were allowed to migrate for 24 hrs. The cells after
fixation and staining were stained counted under 20X magnification Significance of differences
within the cell lines were calculated and statistics represent migration relative to PC3 Mig-3
cells. **p<0.0005 by Student’s t-test, compared to the control group.
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Phosphorylation of FAK Y861 is associated with increased migration of PC3 Mig-3 cells
To determine if pFAK Y861 is required for migration of PC3 Mig-3 cells, I
overexpressed a non-phosphorylatable form of FAK (FAK Y861F) (Figure 23) as described in
the materials and methods. As shown in Figure 24, no effect on proliferation of PC3 Mig-3
FAK Y861F cells was observed. As shown in Figure 25, in vitro migration of PC3 Mig-3 FAK
Y861F cells was reduced by 90% compared to the empty vector control in a 24 hour Boyden
chamber migration assay (p<0.0001), consistent with results from other cell lines demonstrating
the importance of FAK Y861 phosphorylation in migration [78] [93]. These data confirm that
phosphorylation of FAK Y861 regulates migration of PC3 Mig-3 cells.
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Figure 23: Overexpression of FAK Y861F plasmid in the PC3 Mig-3 cells A. Map of the
plenti6/V-5D-TOPO vector used for expression of pFAK Y861F mutant. B. Immunoblot
analysis of FAK Y861F cells to determine the expression of V5-FAK.
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Figure 24: Effects of FAK Y861F expression on cell growth of PC3 Mig-3 cells. PC3 Mig3, PC3 Mig-3 Vector control and FAK Y861F Mig-3 cell lines were equally plated in culture.
The cells were trypsinized and counted after tryphan blue staining for 6 days. The cell numbers
were plotted and the growth rate was determined.
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Figure 25: Effect of FAK Y861F expression in PC3 Mig-3 cells. Migration assay was
performed for 24 hours. Pictures were taken of migrated cells after fixation and staining. The
cells were counted at 20X magnification. Graph illustrates number of cells that have migrated.
Bars represent the average number of cells migrated from triplicate wells. ** p<0.0005,
***p<0.0001 by Student’s t-test, compared to the control group. Representative images are
used to show the number of cells migrating per field.
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Rho-A activation is associated with increased migration of PC3 Mig-3 cells
Rho-A is activated downstream of FAK phosphorylation to induce migration of PC3 cells [132].
To investigate the activation of Rho-A in the PC3 Mig-3 cells, G-LISA Rho-A activation assay
was used. On stimulation of the cells with 10%, FBS had significantly PC3 Mig-3 cells had
significantly higher Rho-A activation relative to PC3-P cells. Additionally the PC3 Mig-3 FAK
Y861F cells were used as a negative control, since they were found to be low migratory in vitro.
As shown in Figure 26, PC3 Mig-3 FAK Y861F cells had significantly less Rho-A activation
relative to the PC3 Mig-3 cells. These data confirmed activation of Rho-A is one of the
downstream pathways that is associated with increased migration in PC3 Mig-3 cells, consistent
with many studies demonstrating the role of Rho-A in mediating FAK migration.
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Figure 26: Rho-A activation status in PC3 Mig-3 cells. PC3-P, PC3 Mig-3 and FAKY861F
Mig-3 cells were equally plated in culture overnight. Rho-A activation was determined using
the G-LISA Rho-A activation assay kit after serum stimulation for 6 mins, 12 mins and 30
mins. Error bars represent average Rho-A activity from triplicate wells.*p<0.005, **p<0.001
by Student’s t-test, compared to the control group.
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Spontaneous metastases of PC3 Mig-3 cells to the lymph nodes are increased in expression
of pFAK Y861
As discussed before, PC3 parental cells are able to metastasize to the lymph node following
orthotopic injection. I therefore determined if the lymph node metastases from PC3-P were also
increased in pFAK Y861. Which would suggest that increased pFAK Y861 is a general property
of lymph node metastasis development. In PC3 Mig-3 cells and PC3-P cells, pFAK Y861
expression in the primary tumors was estimated by immunohistochemistry. As shown in Figure
27, a 2.5-fold increase was observed in expression of pFAK Y861 in the PC3 Mig-3 primary
tumors relative to the PC3-P primary tumors. As PC3-P tumors also form lymph node
metastases, we next examined if these lymph node metastases were selected for increased pFAK
Y861 expression. Immunohistochemistry for pFAK Y861 was performed on tumor-positive
lymph nodes harvested from the metastasis experiment described above. Lymph node
metastasis in PC3-P tumors had a 2.3-fold increase in pFAK Y861 expression relative to the
PC3-P primary tumors. These results demonstrate that lymph node metastases are increased in
expression of pFAK Y861. As expected, in PC3 Mig-3 cells in which pFAK Y861 was already
increased, both primary tumors and lymph node metastases showed high levels of pFAK Y861.
Similar to what was observed in PC3 Mig-3 tumors, pFAK Y861 was also increased in lymph
node metastases, suggesting that overexpression of pFAK Y861 may promote lymph node
metastasis.
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Figure 27: pFAK Y861 expression in mice prostate cancer samples.
A. Immunohistochemical staining for pFAK Y861 expression in primary tumor and lymph
node metastases after orthotopic implantation of PC3-P and PC3 Mig-3 cells in prostate of the
nude mice. B. The staining was quantified after DAB extraction using NIH ImageJ. *p<0.008,
**p<0.001 by Student’s t-test, compared to the control group. PT=parental tumor; LN=lymph
node metastases
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Chapter-5
Elucidating the mechanism of
increased migration in PC3 Mig-3 and
DU145 Mig-3 cells
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Candidate approach to identify proteins associated with increased phosphorylation of FAK
Y861
Phosphorylation of FAK Y861 is one of the signature alterations associated with the
PC3 Mig-3 and DU145 Mig-3 cells. My next goal was to determine whether this increased
phosphorylation was due to increased kinase expression, or decreased phosphatase expression.
The cDNA microarray data performed in collaboration with Woonyoung, Ph.D. and David
McConkey, Ph.D. demonstrated downregulation of Src homology-domain containing tyrosine
phosphatase (Shp-2) in PC3 Mig-3 cells relative to the PC3-P cells. However, immunoblot
analysis indicated that Shp-2 levels were not altered after translation at the protein levels, as
shown in Figure 28 A. These data suggested that Shp-2 was unlikely to be responsible for altered
FAK Y861 phosphorylation in the PC3 Mig-3 phenotype. We next investigated a kinase (PTK6)
reported to associate with pFAK Y861 [128]. As shown in Figure 28 B, immunoblot analysis
indicated that PTK6 was not altered in expression PC3 Mig-3 cells relative to PC3-P cells.
Collectively, these data indicated no alterations in expression levels of Shp-2 and PTK6 are
associated with the PC3 Mig-3 cells.
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Figure 28: Shp-2 and PTK6 expression in PC3 and DU145 cells.
A. Immunoblotting of Shp-2. PC3-P and PC3 Mig-3 were grown in culture. The cells were
lysed and subjected to immunoblot analysis B. Immunoblotting of PTK6. PC3-P and PC3
Mig-3 cells were grown in culture, lysed and 15µg of total protein lysate was subjected to
immunoblot analysis.
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Yes kinase overexpression and increased activity correlates with increased migration in PC3
Mig-3 cells
Src family kinases (SFK’s) phosphorylate all of the FAK tyrosine phosphorylation sites
excluding the autophosphorylation site (FAK Y397) [126]. Hence, I investigated the expression
and activity of SFK’s in PC3 Mig-3 and DU145 Mig-3 cells relative to parental cells.
Expression of SFKs was examined by immunoblot analysis. As shown in Figure 29, no
increased expression of Src, Fyn and Lyn were observed. However, a 2.5-fold increase in Yes
expression was observed in PC3 Mig-3 cells relative to PC3-P cells. Similarly, the DU145 Mig3 cells had a 2-fold increase in Yes expression relative to DU145-P cells, but no increase in
other Src family members expressed in these cells as shown in Figure 30. As determined by rtqPCR, c-yes mRNA was also increased 1.5-fold in the PC3 Mig-3 and DU145 Mig-3 cells
relative to the PC3-P and DU145-P cells, as shown in Figure 31. As FAK is phosphorylated by
SFKs, we next examined kinase activity of Src family members. As antibodies specific to the
autophosphorylation sites (indicative of active forms of these enzymes) to specific SFKs have
not been generated), to examine kinase activity of SFKs expressed in these cells,
immunoprecipitation of individual SFKs was performed using specific antibodies to each and
then blotted with antibody against the autophosphorylation site. This was necessary because the
antibody to the autophosphorylation site recognizes this site in all the SFKs studied. As shown
in Figure 32, no increase in expression or autophosphorylation (indicative of an activated form
of the kinase) was observed for of Src, Lyn and Fyn (Figure 32 B, C, D) in PC3 Mig-3 cells
relative to the PC3-P cells. However, Yes activity was increased by 3-fold in the more migratory
PC3 Mig-3 cells relative to the parental cells (Figure 32 A).
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Figure 29: SFK expression in PC3 cells. A. Immunoblotting of SFK expression PC3-P, PC3
Mig-1, PC3 Mig-2 and PC3 Mig-3 cells were grown in culture and lysed. Total protein was
subjected to immunoblot analysis. B. Quantification of the immunoblot analysis using NIH
ImageJ normalized to the loading control.
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Figure 30: SFK expression in DU145 cells. A. Immunoblotting of SFK expression. DU145P, DU145 Mig-1, DU145 Mig-2 and DU145 Mig-3 cells were grown in culture and lysed. Total
protein was subjected to immunoblot analysis. B. Quantification of the immunoblot analysis
using NIH ImageJ normalized to the loading control.
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Figure 31: Yes mRNA expression in PC3 and DU145 cells. PC3-P, PC3 Mig-3, DU145-P
and DU145 Mig-3 cells were grown in culture. Total RNA from the cells was extracted and
subjected to RT-qPCR using primers specific to Yes kinase. The expression levels are
presented relative to actin control levels **p=0.006, *p=0.002 by Student’s t-test, compared to
the control group.

- 83 -

A.

B.

IP: Yes

IP: Src

IB: Phospho-SFK

IB: Phospho-SFK

C.

D.

IP: Lyn

IP: Fyn

IB: Phospho-SFK

IB: Phospho-SFK

Figure 32: Immunoprecipitation to determine SFK activity. PC3-P and PC3 Mig-3 cells
were grown in culture and lysed. Yes, Src, Lyn and Fyn was immunopreciptated from equal
amounts of protein using specific antibodies for each kinase. Immunoblotting analysis was
performed on the immunoprecipitated lysates to determine the levels of phospho SFK.
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Yes kinase preferentially phosphorylates FAK Y861 in PC3 Mig-3 cells
Next, I investigated the role of Yes kinase in FAK Y861 phosphorylation. As shown in
Figure 33, overexpression of Yes in parental PC3 cells with an expression vector as described
in materials and methods did not increase phosphorylation of FAK Y397, FAK Y401, FAK
Y577 and FAK Y576. However, FAK Y861 phosphorylation was increased by 2.6-fold. In
contrast, overexpression of Src led to an equivalent increase in phosphorylation of all SFK sites,
as shown in Figure 36.
In a second approach to determine if Yes preferentially phosphorylated FAK Y861, Yes
was silenced by in PC3 Mig-3 cells using two Yes specific shRNA sequences. Knockdown of
Yes kinase led to decreased expression of pFAK Y861 and in pFAK Y925 with no significant
effect on expression of the other FAK tyrosine residues, as shown in Figure 34. In contrast,
silencing Src led to decreased phosphorylation of all the SFK phosphorylated FAK tyrosine
residues, represented in Figure 35. To examine the role of Yes in migration, we performed a
migration assay PC3-P cells in which Yes was overexpressed and in PC3 Mig-3 cells in which
Yes was silenced. I found that overexpression of Yes in PC3-P cells led to a 68% (p<0.0001)
increase in migration in PC3-P cells (Figure 37), while knockdown of Yes in PC3 Mig-3 cells
led to a 50% (p<0.0001) reduction in migration in PC3 Mig-3 cells (Figure 38). Collectively,
these data indicate that migration in PC3 Mig-3 cells. These increases and decreases in
migration correlate with the ability of Yes to phosphorylate FAK Y861, and to a lesser extent,
FAK Y925.
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Figure 33: Overexpression of Yes kinase in PC3-P cells A. PC3-P cells were transfected
using the PCMV6-XL5 control and Yes plasmid for 48 hours. The cells were lysed and 15µg
of protein was subjected to immunoblot analysis for Yes and phospho FAK expression. B. The
relative protein expression was determined after normalization against vinculin loading control
using NIH ImageJ.
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Figure 34: Overexpression of Src kinase in PC3 Mig-3 cells. PC3 Mig-3 cells were
transfected with PCDNA3.1 Src expression vector and Non-targeting control plasmids for 24
hours and the cells were trypsinized after 48 hours of transfection. Cell lysates were subjected
to immunoblot analyses for expression of Src and pFAK. Relative protein expression was
determined after normalization to vinculin using NIH ImageJ.

- 87 -

1 .5

R e la tiv e e x p r e ss io n

N T P C 3 M ig -3
s h Y e s # 1 0 0 6 M ig -3
s h Y e s # 1 6 1 1 M ig -3

1 .0

P C 3 M ig -3

0 .5

7

1
57

6/

Y

57

40

5
p

F

A

p

K

F

Y

A

K

Y

92

7
p

F

A

K

Y
K
A
F
p

p

F

A

K

Y

Y

86

39

1

es

0 .0

Figure 35: Knockdown of Yes in PC3 Mig-3 cells. PC3 Mig-3 cells were transfected with
PLKO. puro shYes#1006 and shYes #1611plasmids for 48 hours. The cells were lysed and
subjected to immunoblot analysis for Yes and pFAK expression. Relative protein expression
was determined after normalization again vinculin loading control using NIH ImageJ.
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Figure 36: Knockdown of Src kinase in PC3 Mig-3 cells. PC3 Mig-3 cells were transfected
with shSrc and Non-targeting control plasmids for 24 hrs. Cells were trypsinized after 48 hours
of transfection. Cell lysates were subjected to immunoblot analyses for expression of Src and
pFAK. Relative protein expression was determined after normalization to vinculin using NIH
ImageJ.
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Figure 37: Migration assay of PC3-P cells after overexpression of Yes. PC3-P cells were
transfected with PCMV6-XL5 control and Yes plasmids for 24 hours and the cells were plated
in the Boyden chamber for 24 hours. After 24 hours, the cells were stained and counted to
determine the number of migrating cells. Bars represent the average number of cells migrated
from triplicate wells. ***p<0.0001 by Student’s t-test, compared to the control group.
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Figure 38: Migration assay of PC3-P cells after knockdown of Yes. PC3 Mig-3cells were
transfected with shYes#1006, shYes#1611 and Non-targeting control plasmids for 24 hours
and the cells were plated in the Boyden chamber for 24 hours for migration. After 24 hours,
the cells were stained and counted to determine the number of migrating cells. Bars represent
the average number of cells migrated from triplicate wells. ***p<0.0001 by Student’s t-test,
compared to the control group.
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Src kinase and Yes kinase regulate FAK phosphorylation differently in SYF null mouse
embryonic fibroblasts
While the above experiments provided strong evidence that Yes kinase preferentially
phosphorylates FAK Y861 relative to the other FAK tyrosine sites, these experiments could not
preclude potential roles of other SFKs expressed in prostate cancer cells. Therefore, to further
determine whether Yes and Src differentially phosphorylated FAK, both were transiently
overexpressed in the SYF (src-/-,yes-/-fyn-/-) mouse embryo fibroblasts using expression
plasmids specific for Src and Yes as described in the methods. Overexpression of Src and Yes
is shown in Figure 39. Overexpression of Src in the SYF cells led to increased phosphorylation
of all the SFK-dependent tyrosine phosphorylation sites (Y 861, Y 407, Y 576, Y 577 and Y
925). However, overexpression of Yes kinase led to a 2-fold increase in phosphorylation of
FAK Y861 with a lesser (1.4-fold) increase in phosphorylation of FAK Y 925 (Figure 39); other
sites were not appreciably phosphorylated. These data are consistent with a novel role of Yes
kinase in preferentially phosphorylating FAK Y861 and FAK Y925, the principal tyrosine sites
mediating migration of cells.
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Figure 39: Overexpression of Src and Yes kinase in SYF mouse embryonic fibroblasts.
SYF MEF cells were transfected with PCDNA3.1 Src, pCMV6XL5-Yes and NT control
plasmids for 24 hours and the cells were trypsinized and lysed after 48 hours of transfection.
Cell lysates were subjected to immunoblot analyses for expression of Src and pFAK. Relative
protein expression was determined after normalization to vinculin using NIH ImageJ.
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Yes promotes prostate cancer lymph node metastasis in the orthotopic nude mouse model
To determine whether Yes overexpression promoted lymph node metastases in nude
mouse models, intraprostatic injections were performed as described in materials and methods.
For these experiments, control and Yes silenced cell lines with two different sequences were
transduced with a plasmid directing luciferase expression. Following orthotopic injections,
bioluminescence imaging of mice was performed weekly and mice were sacrificed when the
primary tumors reached similar sizes (Figure 40, 42). A representative image of mice inoculated
with cell lines expressing each construct is shown in Figure 44. Lymph node metastases were
formed in all the groups and, with similar sized primary tumors as shown in Figure 40. NT PC3
Mig-3 cells formed 3.5 ±0.22 lymph node metastasis compared to 1.8± 0.3 lymph node
metastases in the shYes#1006 group and 1.6± 0.2 lymph node metastases in the shYes#1006
group, indicated in Figure 41. Therefore, increased Yes expression is associated with prostate
cancer lymph node metastases.
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Figure 40: Tumorigenicity assay of PC3 Mig-3 cells after silencing Yes. Primary tumor
weights after intraprostatic injection of 1X106 NT PC3 Mig-3, shYes #1006 PC3 Mig-3 and
shYes #1611 PC3 Mig-3 cells. The tumors were grown for 28 days and the mice were
sacrificed.
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Figure 41: Tumorigenicity assay of PC3 Mig-3 cells after silencing Yes. Incidence of lymph
node metastasis after intraprostatic injection of 1X106 NT PC3 Mig-3, shYes #1006 PC3 Mig3 and shYes #1611 PC3 Mig-3 cells. The tumors were grown for 28 days and the mice were
sacrificed. **p<0.001, ***p<0.0001 by ANOVA and Tukey’s test.
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Figure 42: In vivo growth rate of PC3 Mig-3 cells after silencing Yes. Intraprostatic
injections were performed using 1X106 NT PC3 Mig-3, shYes#1006 PC3 Mig-3 and
shYes#1611 PC3 Mig-3 cells. Tumor growth was monitored using luciferase imaging of the
mice every 3 days after injection. Luciferase counts were calculated by selecting region of
interests (ROIs) for each mouse. *p<0.005 by Student’s t-test, compared to the control group.
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NT PC3 Mig-3

shYes PC3 Mig-3

Figure 43: Bioluminescence imaging of PC3 Mig-3 cells after silencing Yes using
luciferase. Representative images from the bioluminescence imaging using luciferase after
intraprostatic injections were performed using 1X106 NT PC3 Mig-3, shYes#1006 PC3 Mig-3
and shYes#1611 PC3 Mig-3 cells. The scales for imaging were standardized for each set.
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Group

Average
Tumor wt.
(mg)/ range

Incidence
of primary
tumor

Average incidence
of LN mets/ range

Incidence of
LN
Metastases

NT PC3 Mig-3

556.7 (490-670)

6/6

3.5 (3-4)**

6/6

sh Yes #1006 PC3 Mig-3

572.8 (436-694)

6/6

1.8 (1-3) **

6/6

sh Yes #1611PC3 Mig-3

604.7 (494-687)

6/6

1.6 (1-3) **

6/6

Table 3: Average weight and incidence of lymph node metastasis after knockdown of Yes
in PC3 Mig-3 cells
ANOVA and Tukey’s test, PC3 Mig-3 compared to PC3-P, **p<0.001
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Figure 44: Representative primary tumors and lymph node metastases when mice were
sacrificed. Luciferase-labeled NT Control PC3 Mig-3 and shYes PC3 Mig-3 cells (1 × 105)
were orthotopically injected into the prostate. Mice were sacrificed when primary tumors
reached similar sizes as monitored by bioluminescence imaging.
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Chapter-6
Yes and pFAK Y861 expression in
human prostate cancer
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To determine the clinical relevance of pFAK Y861 and Yes expression in prostate
cancer lymph node metastasis, I performed immunohistochemical analysis on formalin-fixed
human prostate tumor specimens.
Correlation of pFAK Y861 expression in human prostate cancer patient specimens to survival
To examine the association of pFAK Y861 with patient survival, I collaborated with Dr.
Chien-Jui Cheng and Dr. Sue-Hwa Lin. We examined pFAK Y861 expression in lymph node
metastases of prostate cancer patients. The pFAK Y861 antibody was validated using a negative
control experiment without the primary antibody. Patients were scored for positive (<10% of
pFAK Y861 positive cells) and negative staining (>10% of pFAK Y861 positive cells) for
pFAK Y861 expression. Representative images of lymph node metastases are shown in Figure
46. Patients with positive pFAK Y861 expression had an overall survival 6.13 ±0.99 years. In
contrast patients with negative pFAK Y861 expression), had an overall survival of 11.69±1.67
years, (p=0.008) as represented in Figure 46. These data indicate that high expression of pFAK
Y861 in prostate cancer patients correlate with poor survival.
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Figure 45: pFAK Y861 expression in lymph node metastases in human prostate cancer
Immunohistochemical staining of pFAK Y861 in lymph node metastases.
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Figure 46: Survival analysis of patients with or without expression of pFAK Y861. The
average survival time of cases with FAKpY861 expression is 6.13±0.99 years and in contrast,
the average survival time of cases without FAKpY861 expression is 11.69±1.67 years. p=0.008
(logrank).

- 104 -

Yes expression in human prostate cancer patient specimens
To examine Yes kinase expression in prostate cancer primary tumors and matching
lymph node metastases using a Yes-specific antibody, we obtained human prostate cancer
primary tumor and lymph node metastases samples from the prostate cancer tissue bank at M.
D. Anderson Cancer Center, under an approved IRB protocol. The Yes antibody was validated
for specific staining by using a negative control experiment without using the primary antibody.
Representative images of primary tumors and lymph node metastases are shown in Figure 47.
We used 10 matching sample sets of primary tumors and lymph node metastases for the
analysis. Yes expression was detected in all primary tumors and lymph node metastases. In
addition, high expression was observed in lymphocytes. Average intensity of Yes expression
was calculated after DAB extraction from each sample as described by Park et al. [114]. Yes
expression in lymph node metastases in each set was significantly higher than the matching
primary tumors (p<0.05-p<0.00005), indicated by the matching colors in the graph (Figure 48).
The ratio of Yes expression in the primary tumor to its matching lymph node metastasis was
determined. As shown in Figure 49, Yes expression was increased by 3.2-fold (p<0.005) in the
lymph node metastases relative to the matching primary tumors, similar to what we observed
in the PC3 Mig-3 and DU145 Mig-3 cells versus the parental prostate cancer cells.
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Figure 47: Yes expression in primary tumors and lymph node metastases in human
prostate cancer. Immunohistochemical staining of Yes in primary tumor, lymph node
metastases and matching H&E staining indicating the presence of tumor. The brown DAB
staining indicates membranous localization of Yes kinase.
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Figure 48: Quantification of Yes expression in primary tumors and lymph node
metastases from human prostate cancer specimens. The graph represents average ratio of
Yes expression in primary tumor to the matching lymph node metastasis. Similar color sets
indicate matching lymph node metastasis has significantly higher Yes expression relative to
primary tumors. * p<0.05, **p<0.005, **p<0.0005 by Student’s t-test, compared to the control
group.
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Chapter-7
Discussion
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Metastasis is the cause of mortality in the majority of prostate cancer patients. Because
signature genetic alterations in prostate cancer are rare, understanding regulation of key gene
products associated with metastasis, such as aberrant expression and activity of protein tyrosine
kinases, is critical for prostate cancer progression. Activation of integrins and growth factor
receptors result in activation of the FAK-SFK pathway, which is associated with increased
migration and metastasis of prostate cancer cells. Additionally, in prostate cancer several
pathways downstream of FAK are also activated, indicating that FAK is one of the central
mediators of prostate cancer progression. FAK is overexpressed in metastasis but mutations in
FAK are not found in human tumors and few if any studies have determined whether alterations
in FAK either expression or phosphorylation are truly critical to metastasis. Since, FAK
inhibitors are in clinical trials, understanding how FAK regulates metastasis of prostate cancer
is critical. Hence, I investigated FAK and key elements that regulate FAK to understand its
potential role in processes critical to metastasis.
Classical activation of FAK occurs after integrin clustering or growth factor receptor
activation resulting in autophosphorylation of FAK Y397 and recruitment of SFKs [92]. The
activated FAK-SFK complex then phosphorylates FAK Y401, FAK Y576, FAK Y577, FAK
Y861 and FAK Y925. Phosphorylation of FAK at the SFK-dependent tyrosine residues
discussed above, are known to be equivalent and the role of preferential phosphorylation of the
FAK tyrosine residues in prostate cancer progression is unknown. Previous studies indicate that
Src phosphorylates FAK in vitro [133] and other members of the Src family kinase are predicted
to phosphorylate FAK similarly, however, the role of the different SFKs in regulation of FAK
has not been investigated extensively. Hence, understanding the roles of individual SFKs in
FAK phosphorylation is important, because increased expression of Src, Lyn and Fyn kinase,
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the SFKs are all associated with prostate cancer progression [100, 107, 113, 115, 127].
However, Yes, also known to be expressed in prostate cancer has received much less attention.
Selection of highly migratory variants of prostate cancer cells
To understand the role of FAK in migration and metastasis of prostate cancer, and
possible unique roles for SFKs in regulating FAK, I established cell models that specifically
selected for isogenic variants with increased migration. While, in prior studies by other
investigators, several isogenic cell lines had been isolated from mice with increased metastatic
potential [134, 135], I selected cells through a Boyden chamber with the intent of specifically
focusing on migration, to better understand specifically how FAK and FAK-SFK complexes
that regulate this process. Surprisingly, the migration selection of cells selected for additional
metastatic properties including increased invasion, decreased adhesion, and decreased
proliferation in PC3 Mig-3 and DU145 Mig-3 cells relative to the parental cells. These data led
me to examine the in vivo metastatic ability of PC3 Mig-3 cells in the orthotopic nude mode
model for prostate cancer. I found that PC3 Mig-3 tumors had increased lymph node metastases
relative to the PC3-P tumors confirming that migration selection of prostate cancer cells leads
to selection of more metastatic cells that further highlighted the roles of the FAK/SFK signaling
pathways. It is likely that this occurred because the parental PC3 cells that were used for
selection of the PC3 Mig-3 cells are inherently metastatic. However, it is seems unlikely that
this selection strategy would isolate a highly metastatic cell line from a non-tumorigenic
immortalized line. Future studies could be to attempt this selection strategy in an immortalized
non-tumorigenic cell line such as RWPE, to see if similar changes in FAK occurred, and which
properties are altered due to the migration selection. This type of selection would seem unlikely
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to increase all the properties I examined associated with metastasis, and may provide
information as to the molecular alterations in earlier stages of prostate cancer progression.
Increased phosphorylation of FAK Y861 is a critical alteration associated with more
migratory PC3 Mig-3 and DU145 Mig-3 cells.
Since we established two highly migratory cell models with increased metastatic
potential, I next examined the alterations in FAK-SFK complexes that could be associated with
the PC3 Mig-3 and DU145 Mig-3 cells. Classical activation of FAK requires
autophosphorylation of FAK Y397 leading to phosphorylation of the remaining tyrosine sites
on FAK. However, I found that in the highly migratory PC3 Mig-3 and DU145 Mig-3 cells,
that only phosphorylation of FAK Y861 was increased independent of phosphorylation of FAK
Y397, FAK Y401, FAK Y577, FAK Y576, and FAK Y925. Hence, I focused on understanding
the role of increased phosphorylation of FAK Y861 in migration and metastasis of prostate
cancer cells, discussed in the next sections. Interestingly, the total levels of FAK remained
unaltered. This was an unexpected result given increases in FAK expression is observed in
human prostate cancer metastases [126]. This leads to the question of whether overexpression
of FAK leads to an increase in the number of FAK molecules phosphorylated, and therefore the
phosphorylation, not the expression may be important in prostate cancer metastasis. This could
be tested by overexpressing FAK in a low metastatic cell lines or in a genetically engineered
mouse model that overexpresses FAK and then examining the levels of phosphorylated FAK
Y861 along with the biological changes associated with increased FAK expression.
Additionally, recent data also suggests that nuclear FAK functions as a transcription factor [136]
, and whether this function is associated with tumor progression and metastasis would be an
important question to address.
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To directly test whether pFAK Y861 regulates migration of PC3 Mig-3 cells, we
overexpressed the non-phosphorylatable FAK Y861F mutant in the PC3 Mig-3 cells using a
lentiviral expression vector. Migration assays indicated that inhibition of phosphorylation of
FAK Y861 lead to decreased migration of PC3 Mig-3 cells. Previous studies have indicated that
phosphorylation of FAK Y861 is associated with migration of fibroblasts [93]; however no
cause/effect relationship was established. Our studies have indicated that highly migratory
prostate cancer cell lines may specifically increase phosphorylation of FAK Y861 and this
might be important in FAK-mediated migration of cells.
To further, investigate the role of pFAK Y861 in prostate cancer metastasis, I examined
pFAK Y861 expression in primary tumor and lymph node metastases, and I found a significant
increase in expression of pFAK Y861 in the lymph node metastases relative to the primary
tumors in the parental PC3 cells. These data indicate that similar to the in vitro selection, PC3P cells with high expression of pFAK Y861 were selected to form lymph node metastasis with
increased expression of pFAK Y861. On the contrary, PC3 Mig-3 primary tumors had high
expression of pFAK Y861 and there was no further increase in pFAK Y861 in PC3 Mig-3
lymph node metastasis. This could be occurring as pFAK Y861 might be maximally activated
in the PC3 Mig-3 primary tumors leading to increased lymph node metastasis in this group.
These data confirm that pFAK Y861 expression is associated with metastasis of prostate cancer
cells.
Previous studies from our laboratory have indicated that alterations in several other
oncogenic proteins including Axl and Met are also associated with increased migration and
metastasis of prostate cancer cells [131], and it was possible that these RTKs contributed to the
increased phosphorylation of FAK Y861. Hence, I further investigated the role of Axl and Met
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in PC3 Mig-3 cells in Chapter 4. Using the subcloning approach, I demonstrate that that in spite
of increased expression of Axl and Met in the uncloned population of PC3 Mig-3 cells,
subclones of the same cell line had differential expression of Axl, Met, and the only consistent
alteration associated with increased migration of all the subclones was increased
phosphorylation of FAK Y861. These data indicated that increased phosphorylation of FAK
Y861 is a critical phenomenon occurring downstream of Axl and Met signaling. Our results
suggest that Axl and Met could play a less dominant role in migration than the FAK-SFK
complexes later in tumor progression, after cells have become metastatic. A better
understanding of the roles of Met and Axl might require using cell lines lacking the ability to
metastasize, in which their expression can be genetically manipulated. In line with these
observations, work from our laboratory has shown that knockdown of Met in patient-derived
xenografts from late-stage castrate resistant prostate cancer patients does not affect tumor
growth, suggesting that Met-mediated effects may be at an earlier stage of progression than I
studied. This possibility could be further analyzed by overexpression of Axl and Met in nonmetastatic cells or in cells with lower intrinsic metastatic potential than I used in my thesis.
Yes is overexpressed and has increased activity in migratory cells relative to parental
prostate cancer cells
To examine the mechanism of increased phosphorylation of FAK Y861, I investigated
Src family kinases (SFKs), which are the principal kinases that phosphorylate FAK. SFKs are
recruited to the phosphorylated tyrosine 397 of FAK via the SH2-SFK domain after activation
and subsequently the FAK-SFK complex phosphorylates the remaining tyrosine residues of
FAK. Although in vitro studies indicate that Src phosphorylates FAK [133], less is known about
the role of other SFK members in FAK-mediated functions. As discussed in the introduction,
- 113 -

SFKs have structural and functional similarities; however, studies have identified different roles
of SFKs in in prostate cancer progression [113, 116, 122, 127]. Hence, I examined the
expression levels of the SFK members in PC3 Mig-3 cells. The data indicated that only Yes
kinase was overexpressed and had increased activity in the PC3 Mig-3 and DU145 Mig-3 cells
relative to the parental cells at both protein and RNA levels. Additionally, our previous data
from the subcloning (Figure 21) indicated that increased expression of Yes kinase was a
consistent alteration. This correlates with increased transcription of Yes. The mechanism by
which transcription leads to overexpression of Yes in my migratory variants were increased was
not addressed in this thesis. However, the cDNA array studies performed in collaboration with
Dr. Woonyoung Choi and Dr. David McConkey indicated increased expression of several
transcription factors such as c-MYC, FOXA1 and HEY1 in the PC3 Mig-3 cells relative to the
parental cells. These transcription factors have binding sites on the Yes promoter and could be
important in upregulating transcription of Yes (Figure 52).
The reasoning behind why selection of highly migratory cells also had increased
expression and activity of Yes is also unknown. However I speculate that overexpression and
over activity Yes kinase in the more migratory cells could be because that the other SFKs are
close to maximally activated; and the specific migration selection selected for only the cells that
had increased Yes activity required for preferential phosphorylation of pFAK Y861 and
migration. Future studies could be to perform other selections for additional metastatic
properties such as for adhesion, proliferation, or anoikis and examine whether alterations
associated with other SFKs exist.
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Yes preferentially phosphorylates FAK Y861 in PC3 Mig-3 cells
To directly investigate whether Yes phosphorylates FAK Y861, I first silenced the
expression of Yes kinase in PC3 Mig-3 cells. Knockdown of Yes in the PC3 Mig-3 cells,
preferentially downregulated pFAK Y861 expression and to some extent pFAK Y925
expression indicating that Yes specifically regulates both pFAK Y861 and pFAK Y925 in the
PC3 Mig-3 model. Likewise, overexpression of Yes in PC3-P cells led to increased pFAK Y861
and pFAK Y925 expression. However, while Yes preferentially phosphorylated FAK Y861 and
FAK Y925, the role of Src in phosphorylation of FAK in PC3 Mig-3 cells was not preferential
to FAK Y861 and FAK Y925. I demonstrated that knockdown of Src in PC3 Mig-3 led to
decreased phosphorylation of all the SFK-dependent FAK tyrosine sites and overexpression of
Src lead to increased phosphorylation of all the SFK-dependent FAK tyrosine sites. I speculate
that this Yes-mediated preferential phosphorylation of FAK Y861 and FAK Y925 in PC3 Mig3 occurs because only Yes was overexpressed and had increased activity in PC3 Mig-3 cells
relative to the parental cells. Additionally, previous reports indicate that Yes has weaker specific
kinase activity against exogenous enolase relative to Src kinase in colorectal cancer cells [137],
potentially explaining selective phosphorylation of only FAK Y861 and FAK Y925.
Interestingly, FAK Y925 has also been associated with migration, and many of the signaling
pathways activated through FAK Y861 phosphorylation are activated through FAK Y925
phosphorylation as well. So it is even more interesting that Yes also affects FAK Y925, further
implicating its role in migration. It is unclear why the original selection did not change FAK
Y925 phosphorylation. I speculate that other activating SFKs may have maximally
phosphorylated this tyrosine residue and hence, increase in Yes activity after migration
selection in PC3 cells did not further increase pFAK Y925 levels. Overlapping regulation of
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pFAK Y861 and pFAK Y925 by Yes kinase is likely to occur due to easy accessibility of Yes
kinase to these tyrosine residues as both FAK Y861 and FAK Y925 are present on the FAT
domain of FAK that interacts with additional proteins that form the focal adhesion complex.
Nevertheless, the role of pFAK Y925 in metastasis of prostate cancer cells could be investigated
in the future using site-directed mutagenesis of pFAK Y925 in PC3 Mig-3 cells.
In spite of confirming the role in phosphorylation of FAK Y861 using Yes
overexpression and Yes knockdown experiments, I could not negate the role of the remaining
SFK members in phosphorylation of FAK Y861 and FAK Y925 in the PC3 Mig-3 cells. Hence,
I used the SYF (Src-/-, Yes-/-, Fyn-/-) mouse embryonic fibroblasts model to demonstrate that
overexpression of Yes kinase in the SYF MEF cells led to increased expression of only pFAK
Y861 and pFAK Y925. However, overexpression of Src kinase led to equivalent overexpression
of all the SFK-dependent of FAK phospho-tyrosine sites (Y401, Y577, Y576, Y861 and Y925),
consistent with the PC3 cells. Additionally pFAK Y925 is also critically associated with FAKmediated migration pathways, so despite the failure of the selection to increase FAK Y925
phosphorylation, these data suggests that increased Yes might be critical in regulating
migration.
Yes-mediated migration of PC3 Mig-3 cells
Since, increased Yes expression and activity specifically phosphorylated pFAK Y861
that is associated with the highly migratory PC3 Mig-3 cells, I hypothesized that Yes promotes
migration in prostate cancer cells. To test this hypothesis, I performed migration assays on PC3
Mig-3 and PC3-P cells after silencing and overexpression of Yes respectively. I found that Yes
knockdown in PC3 Mig-3 cells leads to decreased migration, whereas overexpression of Yes in
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PC3-P cells leads to increase in migration. I speculate that Yes regulates migration of prostate
cancer cells by phosphorylation of pFAK Y861 and pFAK Y925, both of which recruit p130
Cas and Paxillin after phosphorylation leading to downstream pathways that regulate the
migration signaling [138]. The role of Yes in phosphorylation and activation of these
downstream signaling pathways mediating migration could be determined in the future by
examining the expression of phospho p130Cas and phospho paxillin after knockdown and
overexpression of Yes kinase in the PC3 Mig-3 cells. In Chapter 4 of this thesis, I also
demonstrate that activation of Rho-A GTPases, which I predict is a possible downstream
signaling mechanism of pFAK Y861 that regulates migration of PC3 Mig-3 cells. The data
indicates that Rho-A was significantly more active in PC3 Mig-3 cells relative to the PC3-P
cells additionally, Rho-A was downregulated in FAK Y861F Mig-3 cells, which had reduced
migration in vitro (Figure 26). However, the role of Rho-A in migration of PC3 Mig-3 cells still
remains unclear, and could be cell line dependent [139-141]. Hence, further studies are required
to determine the role of additional proteins that are involved in regulation of Rho-A downstream
of pFAK Y861.
Yes promotes lymph node metastases of prostate cancer cells
The data from Chapter 4 of this thesis indicate previously unknown roles of Yes kinase
in prostate progression. Yes expression and activity was associated with increased migration of
cells, however these data were correlative. To further investigate whether Yes affected
metastasis in vivo, I performed an in vivo tumorigenicity assay using NT PC3 Mig-3 and shYes
PC3 Mig-3 cells in the orthotopic nude mouse model for prostate cancer. The data indicated
that shYes PC3 Mig-3 cells formed significantly fewer lymph node metastases relative to NT
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PC3 Mig-3 cells similar to PC3-P cells. This provides a strong evidence that the increase in Yes
was responsible for the increased lymph node metastases observed in the PC3 Mig-3 model.
Clinical significance of the study
Finally, to determine if the increased metastasis was a result of Yes expression and was
relevant to human prostate cancer metastasis, I collaborated with Dr. Sue-Hwa Lin and Dr.
Chein-Jui Cheng to examine pFAK Y861 expression in human tissues. We demonstrated that
pFAK Y861 is overexpressed in lymph node metastasis of patients with poor survival (Figure
48, 49). I further demonstrated the clinical significance of Yes overexpression in prostate cancer
progression by staining matched primary tumors and lymph node metastasis with antibody
specific for Yes kinase. Increase in Yes expression in lymph node metastasis relative to the
primary tumors (Figure 51) indicated that, the lymph node metastasis selected for cells
overexpressing Yes kinase and I demonstrated that increased expression of Yes kinase was
associated with prostate cancer lymph node metastasis. Since, very less information regarding
Yes expression in matched primary tumors and lymph node metastases are currently available
in The Cancer Genome Atlas (TCGA) databases, further confirmation for increased expression
of Yes kinase in human prostate cancer progression can be determined by examining Yes
overexpression at the RNA levels in matched primary and lymph node metastasis. mRNA levels
of yes in patient samples can be determined after micro dissection of the tumor areas from the
paraffin embedded tumor tissue and isolation of RNA, followed by RT-qPCR for yes expression
using specific primers.
We specifically examined lymph node metastasis from prostate cancer patients as the
spontaneous metastasis of prostate cancer in the mouse models occurs to the lymph node
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metastasis. Although, lymph node metastasis is not lethal by itself, clinical studies from several
institutions have indicated that lymph node metastasis is a poor prognostic factor of progressionfree survival in patients and is critical in prostate cancer progression [142-145]. Whether,
increased expression of pFAK Y861 and Yes kinase is important in bone metastasis can be
determined experimentally, by performing intracardiac injections of PC3 Mig-3 and DU145
Mig-3 cells in the mice and examining whether PC3 Mig-3 cells colonize to the bone. Clinically,
the significance of increased expression of pFAK Y861 and Yes kinase in bone metastasis of
prostate cancer can be determined by performing immunohistochemistry to determine the
expression of pFAK Y861 and Yes in human prostate cancer bone metastasis.
My study has unexpected clinical relevance, as a recent clinical trial investigating the
role of Dasatinib, a small molecule inhibitor of SFKs did not show significant improvement in
overall survival of metastatic castrate resistant prostate cancer patients. I demonstrate that
increased expression and activity of only Yes kinase and not Src kinase is associated with a
subset of prostate cancer cells, implicating that Src family kinases could be differentially
upregulated in prostate cancer patients as well. This could be important as patients with
upregulation of a specific SFK could respond differently to a pan-SFK inhibitor. Hence,
stratification of patient cohorts depending of expression of different SFK members might be
crucial for the success of future SFK inhibitor clinical trials and improvement of patient
outcomes.
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Future perspectives
This dissertation investigated the role of many proteins in prostate cancer metastasis.
While the role of FAK and Src family kinase have been known to be associated with prostate
cancer metastasis, my work is the first to identify the role of a specifically pFAK Y861 and Yes
kinase in prostate cancer metastasis. However, many questions remain to be determined in the
future.
In vitro migration selection of prostate cancer cells resulted in selection of cells with
additional properties of metastasis. However, whether selection of cells using additional
strategies, for example decreased adhesion, decreased proliferation, or increased anoikis would
lead to selection of more metastatic cells could be another future study. As Src, Fyn and Lyn
are known to play different roles in prostate cancer development, less is known regarding the
role of Yes in this process. The role of Yes in promoting prostate cancer initiation and
progression can be further examined by developing genetically engineered mouse models that
overexpress Yes.
Since, we found increased expression of Yes kinase and pFAK Y861 in prostate cancer
lymph node metastasis with the latter correlating to poor survival of patients, we can examine
if increased expression of Yes kinase or pFAK Y861 in primary prostate tumor biopsies
correlate with poor patient survival. Additionally, understanding whether increased expression
of Yes and pFAK Y861 correlates with bone metastasis would be critical to investigate the role
of these proteins in prostate cancer progression. This could be accomplished by
immunohistochemical analysis of Yes and pFAK Y861 in human prostate cancer bone
metastasis and by examining whether PC3 Mig-3 cells metastasize to the bone after performing
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intracardiac injections of PC3 Mig-3 cells. This study could have a potential application of Yes
and pFAK Y861 as biomarkers to detect prostate cancer progression.
Another approach towards using Yes and pFAK Y861 as biomarkers could be by
detecting Yes kinase and phosphorylated FAK Y861 in the circulating tumor cells (CTCs).
Although, whether Yes or pFAK Y861 are expressed in CTCs is not known, preliminary studies
in our laboratory using antibodies against pFAK Y861 have indicated that expression of pFAK
Y861 can be detected in PC3 prostate cancer cells experimentally introduced in mouse blood.
Therefore, FAK phosphorylation and Yes expression may be a biomarker to predict prognosis
in patients.
In spite of promising preclinical studies, the recent failure of dasatinib in a multinational
phase-3 clinical trial indicates that not all the prostate cancer patients respond to a drug and
selecting the patients that would respond to therapy is critical for improving overall survival of
patients. Since, my study indicates different roles of Yes kinase in prostate cancer progression,
a retrospective analysis of expression of different SFKs in the patients that responded to
dasatinib and the ones that did not respond could be critical understanding the failure of the
trial. Collectively, these studies would support my study that indicates that pFAK Y861 and
Yes expression could not only be drivers of prostate cancer but also biomarkers for metastasis
of prostate cancer
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Conclusions
In this dissertation, I demonstrated that in the highly metastatic PC3 Mig-3 and DU145
Mig-3 cells, increased pFAK Y861 expression was associated with increased metastasis;
however, the levels of total FAK remained unchanged. Using a non-phosphorylatable mutant
of pFAK Y861, I demonstrated that pFAK Y861 is critical for migration of cells. Besides,
increased phosphorylation of pFAK Y861 in lymph node metastasis of prostate cancer patients
correlated with poor survival. These data demonstrate importance of pFAK Y861 in prostate
cancer metastasis. Mechanistically, I demonstrated that specifically Yes kinase is responsible
for preferential phosphorylation of pFAK Y861, indicating different roles of SFK members in
phosphorylation of FAK in the highly migratory PC3 Mig-3 cells. Additionally, Yes kinase also
promoted metastasis in vivo mouse model, directly correlating with its ability to increase
tyrosine phosphorylation of FAK Y861. Finally, increased Yes kinase in lymph node metastases
relative to matched primary tumors in human prostate cancer indicates the clinical relevance of
these findings. In summary, I demonstrated that overexpression of Yes kinase promotes
migration of prostate cancer cells through Yes-mediated preferential phosphorylation of pFAK
Y861 (summarized in Figure 53). Therefore, I conclude that pFAK Y861 and Yes could be
potential targets for development of novel therapies for prostate cancer metastasis.
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Parental PC3/DU145 cells

(1)

PC3 Mig-3/DU145 Mig-3 cells

(2)

Figure 49: Model for preferential phosphorylation of pFAK Y861 in more migratory PC3
Mig-3 and DU145 Mig-3 cells. (1) In the parental PC3 and DU145 cells, Src phosphorylates
all the SFK-dependent tyrosine kinase sites on FAK, (2) In the more migratory PC3 Mig-3 and
DU145 Mig-3 cells, Yes kinase is over expressed and has increased activity leading to
increased phosphorylation of FAK Y861 and increased migration of cells.
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APPENDIX
Microarray analysis
RNA was isolated from the cells using the MirVana RNA extraction kit (Ambion/Life
technologies, Austin,TX, USA). RNA was used for synthesis of biotin-labeled cRNA, using the
Illumina RNA amplification kit (Ambion/Life Technologies, Austin, TX, USA). RNA purity
and integrity were measured by NanoDrop ND-1000 and Agilent Bioanalyzer and only high
quality RNA was used for the cRNA amplification, and then hybridized to Illumina-HT12
(Illumina, Inc., Hayward, CA, USA) chips. Slides were scanned with Bead Station 500X and
signal intensities were quantified with GenomeStudio (Illumina, Inc.). Quantile normalization
in the Linear Models for Microarray Data (LIMMA) package in the R language environment
was used to normalize the data. BRB ArrayTools version 4.2 developed by National Cancer
Institute was used to analyze the data as described by Choi et al.[146]. To identify molecular
subtypes, we subjected the data obtained to unsupervised hierarchical cluster analysis using the
6700 probes that exhibited expression ratios of at least 2-fold relative to the median gene
expression level across all samples in at least six samples. p<0.001 with FDR <0.1, 1.5 fold cutoff was used to determine differentially regulated genes in PC3 Mig-3 and PC3-P cells. To
visualize gene expression patterns, specific gene expression values, adjusted to a median of
zero, were used for clustering using Cluster 3.0 and TreeView (Eisen et al., 1998). Functional
and pathway analyses were performed using Ingenuity Pathway Analysis (IPA) software
(Ingenuity® Systems, CA), which contains a database for identifying networks and pathways
of interest in genomic data.
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Figure 50: Heat-map of the migration and invasion regulating genes. Heat-map indicating
the most differentially regulated genes that are involved in migration and invasion of cells.
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Figure 51: IPA pathway analysis. Pathway analysis indicating cellular movement signaling
pathways as the most significantly altered pathway in the PC3 Mig-3 cells relative to the
parental cells. p<0.001, False discovery rate <0.1
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Figure 52: UCSC genome browser analysis of transcription factors binding to yes
promoter. UCSC genome browser analysis indicating binding of several transcription factors
including HEY1, FOXA1 and c-MYC to the Yes promoter region.
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G-LISA Rho-A activation assay protocol
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